

Antônio López-Beltrán

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2741549/publications.pdf>

Version: 2024-02-01

617
papers

21,246
citations

9786

73
h-index

18130

120
g-index

665
all docs

665
docs citations

665
times ranked

16187
citing authors

#	ARTICLE	IF	CITATIONS
1	The 2005 International Society of Urological Pathology (ISUP) Consensus Conference on Gleason Grading of Prostatic Carcinoma. American Journal of Surgical Pathology, 2005, 29, 1228-1242.	3.7	2,334
2	2004 WHO Classification of the Renal Tumors of the Adults. European Urology, 2006, 49, 798-805.	1.9	728
3	Understanding Pathologic Variants of Renal Cell Carcinoma: Distilling Therapeutic Opportunities from Biologic Complexity. European Urology, 2015, 67, 85-97.	1.9	403
4	Molecular testing for BRAF mutations to inform melanoma treatment decisions: a move toward precision medicine. Modern Pathology, 2018, 31, 24-38.	5.5	324
5	Small cell carcinoma of the urinary bladder. Cancer, 2004, 101, 957-962.	4.1	268
6	The 2004 WHO Classification of Bladder Tumors: A Summary and Commentary. International Journal of Surgical Pathology, 2005, 13, 143-153.	0.8	220
7	Molecular pathology of lung cancer: key to personalized medicine. Modern Pathology, 2012, 25, 347-369.	5.5	215
8	Tuberous Sclerosisâ€“associated Renal Cell Carcinoma. American Journal of Surgical Pathology, 2014, 38, 1457-1467.	3.7	211
9	2009 update on the classification of renal epithelial tumors in adults. International Journal of Urology, 2009, 16, 432-443.	1.0	207
10	Histologic variants of urothelial carcinoma: differential diagnosis and clinical implications. Human Pathology, 2006, 37, 1371-1388.	2.0	201
11	Metabolic phenotype of bladder cancer. Cancer Treatment Reviews, 2016, 45, 46-57.	7.7	201
12	Molecular biology of prostatic intraepithelial neoplasia. , 1996, 29, 117-134.		178
13	Molecular Genetic Evidence for a Common Clonal Origin of Urinary Bladder Small Cell Carcinoma and Coexisting Urothelial Carcinoma. American Journal of Pathology, 2005, 166, 1533-1539.	3.8	175
14	Bladder cancer: translating molecular genetic insights into clinical practice. Human Pathology, 2011, 42, 455-481.	2.0	173
15	Staging and reporting of urothelial carcinoma of the urinary bladder. Modern Pathology, 2009, 22, S70-S95.	5.5	166
16	Molecular Evidence Supporting Field Effect in Urothelial Carcinogenesis. Clinical Cancer Research, 2005, 11, 6512-6519.	7.0	160
17	Non-Invasive Urothelial Neoplasms: According to the Most Recent WHO Classification. European Urology, 2004, 46, 170-176.	1.9	155
18	Best Practices Recommendations in the Application of Immunohistochemistry in the Bladder Lesions. American Journal of Surgical Pathology, 2014, 38, e20-e34.	3.7	155

#	ARTICLE	IF	CITATIONS
19	Best Practices Recommendations in the Application of Immunohistochemistry in Urologic Pathology. American Journal of Surgical Pathology, 2014, 38, 1017-1022.	3.7	155
20	Renal Tumors. American Journal of Surgical Pathology, 2013, 37, 1518-1531.	3.7	154
21	Immune Checkpoint Inhibitors for the Treatment of Bladder Cancer. Cancers, 2021, 13, 131.	3.7	153
22	Multilocular Cystic Renal Cell Carcinoma. American Journal of Clinical Pathology, 2006, 125, 217-222.	0.7	148
23	Standardization of Gleason grading among 337 European pathologists. Histopathology, 2013, 62, 247-256.	2.9	148
24	Evidence for Common Clonal Origin of Multifocal Lung Cancers. Journal of the National Cancer Institute, 2009, 101, 560-570.	6.3	142
25	Thyroid transcription factor 1 expression in small cell carcinoma of the urinary bladder: an immunohistochemical profile of 44 cases. Human Pathology, 2005, 36, 718-723.	2.0	137
26	ERG/TMPRSS2 rearrangement is shared by concurrent prostatic adenocarcinoma and prostatic small cell carcinoma and absent in small cell carcinoma of the urinary bladder: evidence supporting monoclonal origin. Modern Pathology, 2011, 24, 1120-1127.	5.5	130
27	A Working Group Classification of Focal Prostate Atrophy Lesions. American Journal of Surgical Pathology, 2006, 30, 1281-1291.	3.7	123
28	Variants and new entities of bladder cancer. Histopathology, 2019, 74, 77-96.	2.9	120
29	Gleason grading of prostate cancer in needle biopsies or radical prostatectomy specimens: contemporary approach, current clinical significance and sources of pathology discrepancies. BJU International, 2005, 95, 1146-1152.	2.5	118
30	Handling and Staging of Renal Cell Carcinoma. American Journal of Surgical Pathology, 2013, 37, 1505-1517.	3.7	118
31	Staging of bladder cancer. Histopathology, 2019, 74, 112-134.	2.9	117
32	Staging of prostate cancer. Histopathology, 2012, 60, 87-117.	2.9	114
33	Sarcomatoid Carcinoma of the Urinary Bladder. American Journal of Surgical Pathology, 2011, 35, e34-e46.	3.7	112
34	Interobserver Reproducibility in the Diagnosis of Invasive Micropapillary Carcinoma of the Urinary Tract Among Urologic Pathologists. American Journal of Surgical Pathology, 2010, 34, 1367-1376.	3.7	111
35	Immunohistochemical evaluation of novel and traditional markers associated with urothelial differentiation in a spectrum of variants of urothelial carcinoma of the urinary bladder. Human Pathology, 2014, 45, 1473-1482.	2.0	110
36	Handling and Pathology Reporting of Specimens with Carcinoma of the Urinary Bladder, Ureter, and Renal Pelvis. European Urology, 2004, 45, 257-266.	1.9	108

#	ARTICLE	IF	CITATIONS
37	Molecular and cytogenetic insights into the pathogenesis, classification, differential diagnosis, and prognosis of renal epithelial neoplasms. <i>Human Pathology</i> , 2009, 40, 10-29.	2.0	108
38	Update for the practicing pathologist: The International Consultation On Urologic Disease-European association of urology consultation on bladder cancer. <i>Modern Pathology</i> , 2015, 28, 612-630.	5.5	106
39	Intestinal metaplasia is not a strong risk factor for bladder cancer: Study of 53 cases with long-term follow-up. <i>Urology</i> , 1997, 50, 427-431.	1.0	103
40	Plasmacytoid urothelial carcinoma of the bladder. <i>Human Pathology</i> , 2009, 40, 1023-1028.	2.0	103
41	Epigenetic modulations and lineage plasticity in advanced prostate cancer. <i>Annals of Oncology</i> , 2020, 31, 470-479.	1.2	103
42	Preneoplastic non-papillary lesions and conditions of the urinary bladder: an update based on the Ancona International Consultation. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2002, 440, 3-11.	2.8	102
43	Lymphoepithelioma-like carcinoma of the urinary bladder: a clinicopathologic study of 13 cases. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2001, 438, 552-557.	2.8	101
44	Multilocular cystic renal cell carcinoma is a subtype of clear cell renal cell carcinoma. <i>Modern Pathology</i> , 2010, 23, 931-936.	5.5	101
45	Role of Immunohistochemistry in Diagnosing Renal Neoplasms: When Is It Really Useful?. <i>Archives of Pathology and Laboratory Medicine</i> , 2012, 136, 410-417.	2.5	101
46	Androgen Receptor Signaling Pathway in Prostate Cancer: From Genetics to Clinical Applications. <i>Cells</i> , 2020, 9, 2653.	4.1	98
47	Inflammatory Myofibroblastic Tumors of the Kidney: A Clinicopathologic and Immunohistochemical Study of 12 Cases. <i>American Journal of Surgical Pathology</i> , 2003, 27, 658-666.	3.7	96
48	Neuroendocrine tumours of the urinary system and male genital organs: clinical significance. <i>BJU International</i> , 2009, 103, 1464-1470.	2.5	94
49	The plasmacytoid carcinoma of the bladder – rare variant of aggressive urothelial carcinoma. <i>International Journal of Cancer</i> , 2011, 129, 346-354.	5.1	94
50	Soft tissue tumors of the urinary bladder, part I: myofibroblastic proliferations, benign neoplasms, and tumors of uncertain malignant potential. <i>Human Pathology</i> , 2007, 38, 807-823.	2.0	93
51	Workgroup 5: Assessment of prostate carcinoma in core needle biopsy – Definition of minimal criteria for the diagnosis of cancer in biopsy material. <i>Cancer</i> , 1996, 78, 376-381.	4.1	90
52	Molecular Genetic Evidence for the Independent Origin of Multifocal Papillary Tumors in Patients with Papillary Renal Cell Carcinomas. <i>Clinical Cancer Research</i> , 2005, 11, 7226-7233.	7.0	89
53	Lymphoepithelioma-like Carcinoma of the Urinary Bladder. <i>American Journal of Surgical Pathology</i> , 2011, 35, 474-483.	3.7	88
54	Distinguishing primary adenocarcinoma of the urinary bladder from secondary involvement by colorectal adenocarcinoma: extended immunohistochemical profiles emphasizing novel markers. <i>Modern Pathology</i> , 2013, 26, 725-732.	5.5	88

#	ARTICLE	IF	CITATIONS
55	Biomarkers in bladder cancer: Translational and clinical implications. <i>Critical Reviews in Oncology/Hematology</i> , 2014, 89, 73-111.	4.4	88
56	Urothelial dysplasia and other flat lesions of the urinary bladder: clinicopathologic and molecular features. <i>Human Pathology</i> , 2010, 41, 155-162.	2.0	86
57	<i>KIT</i> gene mutation and amplification in dysgerminoma of the ovary. <i>Cancer</i> , 2011, 117, 2096-2103.	4.1	85
58	Prognostic and Therapeutic Impact of the Histopathologic Definition of Parenchymal Epithelial Renal Tumors. <i>European Urology</i> , 2010, 58, 655-668.	1.9	84
59	Divergent pathway of intestinal metaplasia and cystitis glandularis of the urinary bladder. <i>Modern Pathology</i> , 2006, 19, 1395-1401.	5.5	83
60	Urothelial Carcinoma With an Inverted Growth Pattern Can be Distinguished From Inverted Papilloma by Fluorescence In Situ Hybridization, Immunohistochemistry, and Morphologic Analysis. <i>American Journal of Surgical Pathology</i> , 2007, 31, 1861-1867.	3.7	82
61	Inflammatory Myofibroblastic Tumors of the Genitourinary Tract—Single Entity or Continuum?. <i>Journal of Urology</i> , 2008, 180, 1235-1240.	0.4	81
62	Multilocular Cystic Renal Cell Carcinoma : A Report of 45 Cases of a Kidney Tumor of Low Malignant Potential. <i>American Journal of Clinical Pathology</i> , 2006, 125, 217-222.	0.7	81
63	Soft tissue tumors of the urinary bladder. <i>Human Pathology</i> , 2007, 38, 963-977.	2.0	79
64	Bladder cancer: Clinical and pathological profile. <i>Scandinavian Journal of Urology and Nephrology</i> , 2008, 42, 95-109.	1.4	79
65	Immunohistochemical profile to distinguish urothelial from squamous differentiation in carcinomas of urothelial tract. <i>Human Pathology</i> , 2013, 44, 164-172.	2.0	79
66	Natural history of urothelial inverted papilloma. <i>Cancer</i> , 2006, 107, 2622-2627.	4.1	78
67	Histogenesis of Clear Cell Adenocarcinoma in the Urinary Tract: Evidence of Urothelial Origin. <i>Clinical Cancer Research</i> , 2008, 14, 1947-1955.	7.0	78
68	Current Pathology Keys of Renal Cell Carcinoma. <i>European Urology</i> , 2011, 60, 634-643.	1.9	78
69	Histologic grading of urothelial carcinoma: a reappraisal. <i>Human Pathology</i> , 2012, 43, 2097-2108.	2.0	78
70	<i>BAP1</i> , <i>PBRM1</i> and <i>SETD2</i> in clear-cell renal cell carcinoma: molecular diagnostics and possible targets for personalized therapies. <i>Expert Review of Molecular Diagnostics</i> , 2015, 15, 1201-1210.	3.1	78
71	Epithelial to Mesenchymal Transition in Renal Cell Carcinoma: Implications for Cancer Therapy. <i>Molecular Diagnosis and Therapy</i> , 2016, 20, 111-117.	3.8	77
72	PD-L1 assessment in urothelial carcinoma: a practical approach. <i>Annals of Translational Medicine</i> , 2019, 7, 690-690.	1.7	77

#	ARTICLE	IF	CITATIONS
73	Epidermal Growth Factor Receptor Protein Expression and Gene Amplification in Small Cell Carcinoma of the Urinary Bladder. <i>Clinical Cancer Research</i> , 2007, 13, 953-957.	7.0	76
74	Immune checkpoint inhibitors for metastatic bladder cancer. <i>Cancer Treatment Reviews</i> , 2018, 64, 11-20.	7.7	76
75	Mechanisms of Disease: high-grade prostatic intraepithelial neoplasia and other proposed preneoplastic lesions in the prostate. <i>Nature Reviews Urology</i> , 2007, 4, 321-332.	1.4	75
76	Multilocular Cystic Renal Cell Carcinoma. <i>American Journal of Surgical Pathology</i> , 2012, 36, 1425-1433.	3.7	75
77	Prognostic Factors in Survival of Patients With Stage Ta and T1 Bladder Urothelial Tumors. <i>American Journal of Clinical Pathology</i> , 2004, 122, 444-452.	0.7	74
78	c-kit Expression in small cell carcinoma of the urinary bladder: prognostic and therapeutic implications. <i>Modern Pathology</i> , 2005, 18, 320-323.	5.5	74
79	Invasive micropapillary urothelial carcinoma of the bladder. <i>Human Pathology</i> , 2010, 41, 1159-1164.	2.0	73
80	p16 expression is not associated with human papillomavirus in urinary bladder squamous cell carcinoma. <i>Modern Pathology</i> , 2012, 25, 1526-1533.	5.5	73
81	Malignant Perivascular Epithelioid Cell Neoplasm (PEComa) of the Urinary Bladder With TFE3 Gene Rearrangement. <i>American Journal of Surgical Pathology</i> , 2013, 37, 1619-1626.	3.7	73
82	Secondary neoplasms of the urinary system and male genital organs. <i>BJU International</i> , 2009, 104, 770-776.	2.5	72
83	The origins of urothelial carcinoma. <i>Expert Review of Anticancer Therapy</i> , 2010, 10, 865-880.	2.4	72
84	Current Strategies and Novel Therapeutic Approaches for Metastatic Urothelial Carcinoma. <i>Cancers</i> , 2020, 12, 1449.	3.7	72
85	Primary Mediastinal Seminoma: A Comprehensive Assessment Integrated With Histology, Immunohistochemistry, and Fluorescence In Situ Hybridization for Chromosome 12p Abnormalities in 23 Cases. <i>American Journal of Surgical Pathology</i> , 2008, 32, 146-155.	3.7	71
86	Atypical Foci Suspicious but not Diagnostic of Malignancy in Prostate Needle Biopsies. <i>European Urology</i> , 2006, 50, 666-674.	1.9	69
87	The relationship between the extent of surgical margin positivity and prostate specific antigen recurrence in radical prostatectomy specimens. <i>Human Pathology</i> , 2007, 38, 1207-1211.	2.0	69
88	TP53 mutational analysis supports monoclonal origin of biphasic sarcomatoid urothelial carcinoma (carcinosarcoma) of the urinary bladder. <i>Modern Pathology</i> , 2009, 22, 113-118.	5.5	68
89	Updates in the Pathologic Diagnosis and Classification of Epithelial Neoplasms of Urachal Origin. <i>Advances in Anatomic Pathology</i> , 2016, 23, 71-83.	4.3	67
90	Cystic Nephroma and Mixed Epithelial and Stromal Tumour of the Kidney: Opposite Ends of the Spectrum of the Same Entity?. <i>European Urology</i> , 2008, 54, 1237-1246.	1.9	65

#	ARTICLE	IF	CITATIONS
91	Pathology and Genetics: Tumours of the Urinary System and Male Genital System. <i>European Urology</i> , 2016, 70, 120-123.	1.9	65
92	Is There a Role for Immunotherapy in Prostate Cancer?. <i>Cells</i> , 2020, 9, 2051.	4.1	65
93	Squamous differentiation in primary urothelial carcinoma of the urinary tract as seen by MAC387 immunohistochemistry. <i>Journal of Clinical Pathology</i> , 2006, 60, 332-335.	2.0	64
94	Telomere Shortening and Chromosomal Abnormalities in Intestinal Metaplasia of the Urinary Bladder. <i>Clinical Cancer Research</i> , 2007, 13, 6232-6236.	7.0	64
95	Laser-assisted Microdissection in Translational Research. <i>Applied Immunohistochemistry and Molecular Morphology</i> , 2013, 21, 31-47.	1.2	63
96	Neuroendocrine Tumors of the Prostate: Emerging Insights from Molecular Data and Updates to the 2016 World Health Organization Classification. <i>Endocrine Pathology</i> , 2016, 27, 123-135.	9.0	63
97	Immunotherapy in renal cell carcinoma: latest evidence and clinical implications. <i>Drugs in Context</i> , 2018, 7, 1-8.	2.2	63
98	Urothelial Carcinoma of the Bladder, Lipid Cell Variant: Clinicopathologic Findings and LOH Analysis. <i>American Journal of Surgical Pathology</i> , 2010, 34, 371-376.	3.7	62
99	Interactive digital slides with heat maps: a novel method to improve the reproducibility of Gleason grading. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2011, 459, 175-182.	2.8	60
100	Prostatic adenocarcinoma with atrophic features: malignancy mimicking a benign process. <i>American Journal of Surgical Pathology</i> , 1997, 21, 931-935.	3.7	60
101	Stage pT1 bladder carcinoma: diagnostic criteria, pitfalls and prognostic significance. <i>Pathology</i> , 2003, 35, 484-491.	0.6	59
102	Inverted papilloma of the urinary bladder: a molecular genetic appraisal. <i>Modern Pathology</i> , 2006, 19, 1289-1294.	5.5	59
103	Ureteral endometriosis: clinicopathological and immunohistochemical study of 7 cases. <i>Human Pathology</i> , 2008, 39, 954-959.	2.0	59
104	Glandular lesions of the urinary bladder: clinical significance and differential diagnosis. <i>Histopathology</i> , 2011, 58, 811-834.	2.9	59
105	The reasons behind variation in Gleason grading of prostatic biopsies: areas of agreement and misconception among 266 European pathologists. <i>Histopathology</i> , 2014, 64, 405-411.	2.9	59
106	Role of STAT3 pathway in genitourinary tumors. <i>Future Science OA</i> , 2015, 1, FSO15.	1.9	58
107	Loss of expression of the SWI/SNF complex is a frequent event in undifferentiated/dedifferentiated urothelial carcinoma of the urinary tract. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2016, 469, 321-330.	2.8	58
108	Rare and unusual histological variants of prostatic carcinoma: clinical significance. <i>BJU International</i> , 2008, 102, 1369-1374.	2.5	56

#	ARTICLE	IF	CITATIONS
109	Current practice of Gleason grading of prostate carcinoma. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2006, 448, 111-118.	2.8	55
110	Is Incidentally Detected Prostate Cancer in Patients Undergoing Radical Cystoprostatectomy Clinically Significant?. <i>American Journal of Clinical Pathology</i> , 2009, 131, 279-283.	0.7	55
111	Small Cell Carcinoma of the Urinary Bladder—Histogenesis, Genetics, Diagnosis, Biomarkers, Treatment, and Prognosis. <i>Applied Immunohistochemistry and Molecular Morphology</i> , 2007, 15, 8-18.	1.2	54
112	Telomerase reverse transcriptase (<sc>TERT</sc>) promoter mutation analysis of benign, malignant and reactive urothelial lesions reveals a subpopulation of inverted papilloma with immortalizing genetic change. <i>Histopathology</i> , 2016, 69, 107-113.	2.9	54
113	Clinical Utility of Immunohistochemistry in the Diagnoses of Urinary Bladder Neoplasia. <i>Applied Immunohistochemistry and Molecular Morphology</i> , 2010, 18, 401-410.	1.2	54
114	Morphological classification and definition of benign, preneoplastic and non-invasive neoplastic lesions of the urinary bladder. <i>Histopathology</i> , 2008, 53, 621-633.	2.9	53
115	New Prostate Cancer Targets for Diagnosis, Imaging, and Therapy: Focus on Prostate-Specific Membrane Antigen. <i>Frontiers in Oncology</i> , 2018, 8, 653.	2.8	53
116	Microcystic urothelial carcinoma: morphology, immunohistochemistry and clinical behaviour. <i>Histopathology</i> , 2014, 64, 872-879.	2.9	52
117	Pleomorphic giant cell carcinoma of the urinary bladder. <i>Human Pathology</i> , 2009, 40, 1461-1466.	2.0	50
118	Ectopic prostatic tissue: histogenesis and histopathological characteristics. <i>Histopathology</i> , 2011, 58, 750-758.	2.9	50
119	Update of the International Consultation on Urological Diseases on bladder cancer 2018: non-urothelial cancers of the urinary bladder. <i>World Journal of Urology</i> , 2019, 37, 107-114.	2.2	50
120	Germ Cell Origin of Testicular Carcinoid Tumors. <i>Clinical Cancer Research</i> , 2008, 14, 1393-1396.	7.0	49
121	Prostatic intraepithelial neoplasia: its morphological and molecular diagnosis and clinical significance. <i>BJU International</i> , 2011, 108, 1394-1401.	2.5	49
122	Urethral caruncle: clinicopathologic features of 41 cases. <i>Human Pathology</i> , 2012, 43, 1400-1404.	2.0	49
123	Pathological variants of invasive bladder cancer according to their suggested clinical significance. <i>BJU International</i> , 2008, 101, 275-281.	2.5	47
124	FGFR3 and TP53 mutation analysis in inverted urothelial papilloma: incidence and etiological considerations. <i>Modern Pathology</i> , 2009, 22, 627-632.	5.5	47
125	The landscape of <i>EGFR</i> pathways and personalized management of non-small-cell lung cancer. <i>Future Oncology</i> , 2011, 7, 519-541.	2.4	47
126	Neonatal exposure of male rats to estradiol benzoate causes rete testis dilation and backflow impairment of spermatogenesis. , 1998, 252, 17-33.		46

#	ARTICLE	IF	CITATIONS
127	Pleomorphic Giant Cell Carcinoma of the Prostate. Archives of Pathology and Laboratory Medicine, 2005, 129, 683-685.	2.5	46
128	BCL-2, TP53 and BAX protein expression in superficial urothelial bladder carcinoma. Cancer Letters, 2007, 250, 292-299.	7.2	45
129	Molecular determinants of tumor recurrence in the urinary bladder. Future Oncology, 2009, 5, 843-857.	2.4	45
130	Overexpression of ELAV-like Protein HuR is Associated with Increased COX-2 Expression in Atrophy, High-grade Prostatic Intraepithelial Neoplasia, and Incidental Prostate Cancer in Cystoprostatectomies. European Urology, 2009, 56, 105-112.	1.9	45
131	Utility of whole slide imaging and virtual microscopy in prostate pathology. Apmis, 2012, 120, 298-304.	2.0	45
132	Frequent TMPRSS2-ERG rearrangement in prostatic small cell carcinoma detected by fluorescence in situ hybridization: the superiority of fluorescence in situ hybridization over ERG immunohistochemistry. Human Pathology, 2013, 44, 2227-2233.	2.0	45
133	Prostatic adenocarcinoma with glomeruloid features. Human Pathology, 1998, 29, 543-546.	2.0	44
134	Clonal origin of lymph node metastases in bladder carcinoma. Cancer, 2005, 104, 1901-1910.	4.1	44
135	KISS1 Methylation and Expression as Tumor Stratification Biomarkers and Clinical Outcome Prognosticators for Bladder Cancer Patients. American Journal of Pathology, 2011, 179, 540-546.	3.8	44
136	Evidence for Polyclonal Origin of Multifocal Clear Cell Renal Cell Carcinoma. Clinical Cancer Research, 2008, 14, 8087-8093.	7.0	43
137	Diagnosis, evaluation and treatment of carcinoma in situ of the urinary bladder: The state of the art. Critical Reviews in Oncology/Hematology, 2010, 76, 112-126.	4.4	43
138	Multiplexed Methylation Profiles of Tumor Suppressor Genes in Bladder Cancer. Journal of Molecular Diagnostics, 2011, 13, 29-40.	2.8	43
139	Histopathological findings after treatment of prostate cancer using high-intensity focused ultrasound (HIFU). Prostate, 2010, 70, 1196-1200.	2.3	42
140	Urothelial lesions with inverted growth patterns: histogenesis, molecular genetic findings, differential diagnosis and clinical management. BJU International, 2011, 107, 532-537.	2.5	42
141	Downregulation of Fc γ Receptor IIIA \pm (CD16-II) on Natural Killer Cells Induced by Anti-CD16 mAb Is Independent of Protein Tyrosine Kinases and Protein Kinase C. Cellular Immunology, 1994, 158, 208-217.	3.0	41
142	Prognostic Factors in Survival of Patients With Stage Ta and T1 Bladder Urothelial Tumors The Role of G 1 -S Modulators (p53, P21Waf1, p27Kip1, Cyclin D1, and Cyclin D3), Proliferation Index and Clinicopathologic Parameters. American Journal of Clinical Pathology, 2004, 122, 444-452.	0.7	41
143	Search for residual prostate cancer on pT0 radical prostatectomy after positive biopsy. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2007, 450, 371-378.	2.8	41
144	Strong immunohistochemical expression of fibroblast growth factor receptor 3, superficial staining pattern of cytokeratin 20, and low proliferative activity define those papillary urothelial neoplasms of low malignant potential that do not recur. Cancer, 2008, 112, 636-644.	4.1	41

#	ARTICLE	IF	CITATIONS
145	Intraductal carcinoma of the prostate: interobserver reproducibility survey of 39 urologic pathologists. <i>Annals of Diagnostic Pathology</i> , 2014, 18, 333-342.	1.3	41
146	Handling and reporting of orchidectomy specimens with testicular cancer: areas of consensus and variation among 25 experts and 225 European pathologists. <i>Histopathology</i> , 2015, 67, 313-324.	2.9	41
147	Urothelial carcinoma following augmentation cystoplasty: an aggressive variant with distinct clinicopathological characteristics and molecular genetic alterations. <i>Histopathology</i> , 2009, 55, 161-173.	2.9	40
148	The Identification of Immunological Biomarkers in Kidney Cancers. <i>Frontiers in Oncology</i> , 2018, 8, 456.	2.8	40
149	Flat urothelial carcinoma in situ of the bladder with glandular differentiation. <i>Human Pathology</i> , 2011, 42, 1653-1659.	2.0	38
150	Unclassified renal cell carcinoma: a report of 56 cases. <i>BJU International</i> , 2012, 110, 786-793.	2.5	38
151	Neuroendocrine differentiation in prostate cancer: Novel morphological insights and future therapeutic perspectives. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2014, 1846, 630-637.	7.4	38
152	Predicting outcomes in non-muscle invasive (Ta/T1) bladder cancer: the role of molecular grade based on luminal/basal phenotype. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2019, 475, 445-455.	2.8	38
153	The Human Microbiota and Prostate Cancer: Friend or Foe?. <i>Cancers</i> , 2019, 11, 459.	3.7	38
154	Molecular Mechanisms Related to Hormone Inhibition Resistance in Prostate Cancer. <i>Cells</i> , 2019, 8, 43.	4.1	38
155	Prostate carcinoma II: prognostic factors in prostate needle biopsies. <i>BJU International</i> , 2006, 97, 492-497.	2.5	37
156	Identification of PMF1 Methylation in Association with Bladder Cancer Progression. <i>Clinical Cancer Research</i> , 2008, 14, 8236-8243.	7.0	37
157	PAX8 is expressed in the majority of renal epithelial neoplasms: an immunohistochemical study of 223 cases using a mouse monoclonal antibody. <i>Journal of Clinical Pathology</i> , 2012, 65, 254-256.	2.0	37
158	Handling and reporting of nephrectomy specimens for adult renal tumours: a survey by the European Network of Uro-pathology. <i>Journal of Clinical Pathology</i> , 2012, 65, 106-113.	2.0	37
159	Novel markers of squamous differentiation in the urinary bladder. <i>Human Pathology</i> , 2013, 44, 1989-1997.	2.0	37
160	Amplifications of EGFR gene and protein expression of EGFR, Her-2/neu, c-kit, and androgen receptor in phyllodes tumor of the prostate. <i>Modern Pathology</i> , 2007, 20, 175-182.	5.5	36
161	An interobserver reproducibility study on invasiveness of bladder cancer using virtual microscopy and heatmaps. <i>Histopathology</i> , 2013, 63, 756-766.	2.9	35
162	TERT Promoter Mutations Occur Frequently in Urothelial Papilloma and Papillary Urothelial Neoplasm of Low Malignant Potential. <i>European Urology</i> , 2017, 71, 497-498.	1.9	35

#	ARTICLE	IF	CITATIONS
163	Laser capture microdissection in the genomic and proteomic era: targeting the genetic basis of cancer. <i>International Journal of Clinical and Experimental Pathology</i> , 2008, 1, 475-88.	0.5	35
164	Evidence for Transformation of Fibroadenoma of the Breast to Malignant Phyllodes Tumor. <i>Applied Immunohistochemistry and Molecular Morphology</i> , 2009, 17, 345-350.	1.2	34
165	Understanding the molecular genetics of renal cell neoplasia: implications for diagnosis, prognosis and therapy. <i>Expert Review of Anticancer Therapy</i> , 2010, 10, 843-864.	2.4	34
166	Unique clinicopathologic and molecular characteristics of urinary bladder tumors in children and young adults. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2013, 31, 414-426.	1.6	34
167	Morphologic, Molecular and Clinical Features of Aggressive Variant Prostate Cancer. <i>Cells</i> , 2020, 9, 1073.	4.1	34
168	Towards a new WHO classification of renal cell tumor: what the clinician needs to know”a narrative review. <i>Translational Andrology and Urology</i> , 2021, 10, 1506-1520.	1.4	34
169	Hypermethylation of tumor-suppressor gene CpG islands in small-cell carcinoma of the urinary bladder. <i>Modern Pathology</i> , 2008, 21, 355-362.	5.5	33
170	Small cell carcinoma of the urinary bladder. <i>Histology and Histopathology</i> , 2010, 25, 217-21.	0.7	33
171	Mixed Epithelial and Stromal Tumors of the Kidney. <i>American Journal of Surgical Pathology</i> , 2011, 35, 1114-1122.	3.7	31
172	Handling and reporting of transurethral resection specimens of the bladder in Europe: a web-based survey by the European Network of Urology (ENUP). <i>Histopathology</i> , 2011, 58, 579-585.	2.9	31
173	Mirna Expression in Bladder Cancer and Their Potential Role in Clinical Practice. <i>Current Drug Metabolism</i> , 2017, 18, 712-722.	1.2	31
174	Sarcomatoid carcinoma of the upper urinary tract: clinical outcome and molecular characterization. <i>Human Pathology</i> , 2009, 40, 211-217.	2.0	30
175	The origin of prostate metastases: emerging insights. <i>Cancer and Metastasis Reviews</i> , 2015, 34, 765-773.	5.9	30
176	Epidermal growth factor receptor (EGFR) expression in prostatic adenocarcinoma after hormonal therapy: A fluorescence in situ hybridization and immunohistochemical analysis. <i>Prostate</i> , 2008, 68, 919-923.	2.3	29
177	Urothelial and incidental prostate carcinoma in prostates from cystoprostatectomies for bladder cancer: is there a relationship between urothelial and prostate cancer?. <i>BJU International</i> , 2009, 103, 1058-1063.	2.5	29
178	Cystic partially regressed clear cell renal cell carcinoma: a potential mimic of multilocular cystic renal cell carcinoma. <i>Histopathology</i> , 2013, 63, 767-779.	2.9	29
179	Intraductal carcinoma of prostate reporting practice: a survey of expert European urologists. <i>Journal of Clinical Pathology</i> , 2016, 69, 852-857.	2.0	29
180	Resistance to Systemic Agents in Renal Cell Carcinoma Predict and Overcome Genomic Strategies Adopted by Tumor. <i>Cancers</i> , 2019, 11, 830.	3.7	29

#	ARTICLE	IF	CITATIONS
181	Increased androgen receptor gene copy number is associated with <i>TMPRSS2-ERG</i> rearrangement in prostatic small cell carcinoma. <i>Molecular Carcinogenesis</i> , 2015, 54, 900-907.	2.7	28
182	Tp53 and its potential therapeutic role as a target in bladder cancer. <i>Expert Opinion on Therapeutic Targets</i> , 2017, 21, 401-414.	3.4	28
183	RAS genes in colorectal carcinoma: pathogenesis, testing guidelines and treatment implications. <i>Journal of Clinical Pathology</i> , 2019, 72, 135-139.	2.0	28
184	Oncotargets in Different Renal Cancer Subtypes. <i>Current Drug Targets</i> , 2015, 16, 125-135.	2.1	28
185	Critical Evaluation of the Prostate from Cystoprostatectomies for Bladder Cancer: Insights from a Complete Sampling with the Whole Mount Technique. <i>European Urology</i> , 2009, 55, 1305-1309.	1.9	27
186	Adjuvant and neoadjuvant approaches for urothelial cancer: Updated indications and controversies. <i>Cancer Treatment Reviews</i> , 2018, 68, 80-85.	7.7	27
187	Prognostic factors in survival of bladder cancer. <i>Cancer</i> , 1992, 70, 799-807.	4.1	26
188	Handling and pathology reporting of specimens with carcinoma of the urinary bladder, ureter, and renal pelvis. A joint proposal of the European Society of Uro pathology and the Uro pathology Working Group. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2004, 445, 103-10.	2.8	26
189	Prostate carcinoma I: prognostic factors in radical prostatectomy specimens and pelvic lymph nodes. <i>BJU International</i> , 2006, 97, 485-491.	2.5	26
190	Immunohistochemical Expression of Endothelin-1 and Endothelin-A and Endothelin-B Receptors in High-Grade Prostatic Intraepithelial Neoplasia and Prostate Cancer. <i>European Urology</i> , 2007, 52, 1682-1690.	1.9	26
191	Large cell undifferentiated carcinoma of the urinary bladder. <i>Pathology</i> , 2010, 42, 364-368.	0.6	26
192	Do Not Misinterpret Intraductal Carcinoma of the Prostate as High-grade Prostatic Intraepithelial Neoplasia!. <i>European Urology</i> , 2012, 62, 518-522.	1.9	26
193	Prostate needle biopsy processing: a survey of laboratory practice across Europe. <i>Journal of Clinical Pathology</i> , 2013, 66, 120-123.	2.0	26
194	Adult primary paratesticular mesenchymal tumors with emphasis on a case presentation and discussion of spermatic cord leiomyosarcoma. <i>Diagnostic Pathology</i> , 2014, 9, 90.	2.0	26
195	Prostate cancer: from Gleason scoring to prognostic grade grouping. <i>Expert Review of Anticancer Therapy</i> , 2016, 16, 433-440.	2.4	26
196	Novel Therapeutic Approaches and Targets Currently Under Evaluation for Renal Cell Carcinoma: Waiting for the Revolution. <i>Clinical Drug Investigation</i> , 2019, 39, 503-519.	2.2	26
197	The Role of Obesity in Renal Cell Carcinoma Patients: Clinical-Pathological Implications. <i>International Journal of Molecular Sciences</i> , 2019, 20, 5683.	4.1	26
198	Inflammatory Pseudotumor of the Urinary Bladder. <i>Urologia Internationalis</i> , 1995, 55, 173-176.	1.3	25

#	ARTICLE	IF	CITATIONS
199	Î±-Methylacyl Coenzyme A Racemase, Ki-67, and Topoisomerase IIÎ± in Cystoprostatectomies With Incidental Prostate Cancer. <i>American Journal of Clinical Pathology</i> , 2007, 128, 657-664.	0.7	25
200	Lymphoepithelioma-like carcinoma of the prostate. <i>Human Pathology</i> , 2009, 40, 982-987.	2.0	25
201	Is atypical adenomatous hyperplasia of the prostate a precursor lesion?. <i>Prostate</i> , 2011, 71, 1746-1751.	2.3	25
202	Iatrogenic changes in the urinary tract. <i>Histopathology</i> , 2017, 70, 10-25.	2.9	25
203	Small-cell Carcinomas of the Urinary Bladder and Prostate: TERT Promoter Mutation Status Differentiates Sites of Malignancy and Provides Evidence of Common Clonality Between Small-cell Carcinoma of the Urinary Bladder and Urothelial Carcinoma. <i>European Urology Focus</i> , 2018, 4, 880-888.	3.1	25
204	Digital pathology and COVID-19 and future crises: pathologists can safely diagnose cases from home using a consumer monitor and a mini PC. <i>Journal of Clinical Pathology</i> , 2020, 73, 695-696.	2.0	25
205	Neoplasms of the urinary bladder. , 2008, , 258-351.		25
206	Targeting the Programmed Cell Death-1 Pathway in Genitourinary Tumors: Current Progress and Future Perspectives. <i>Current Drug Metabolism</i> , 2017, 18, 700-711.	1.2	25
207	BLADDER TREATMENT. <i>Urologic Clinics of North America</i> , 1999, 26, 535-554.	1.8	24
208	Solitary Fibrous Tumour of the Prostate Identified on Needle Biopsy. <i>European Urology</i> , 2009, 56, 564-567.	1.9	24
209	The clinical and therapeutic implications of cancer stem cell biology. <i>Expert Review of Anticancer Therapy</i> , 2011, 11, 1133-1145.	2.4	24
210	T1 high-grade bladder carcinoma outcome: the role of p16, topoisomerase-II Î± , survivin, and E-cadherin. <i>Human Pathology</i> , 2016, 57, 78-84.	2.0	24
211	Exploring Small Extracellular Vesicles for Precision Medicine in Prostate Cancer. <i>Frontiers in Oncology</i> , 2018, 8, 221.	2.8	24
212	Current and emerging bladder cancer biomarkers with an emphasis on urine biomarkers. <i>Expert Review of Molecular Diagnostics</i> , 2020, 20, 231-243.	3.1	24
213	Digital Biopsy with Fluorescence Confocal Microscope for Effective Real-time Diagnosis of Prostate Cancer: A Prospective, Comparative Study. <i>European Urology Oncology</i> , 2021, 4, 784-791.	5.4	24
214	Clinicopathologic analysis of upper urinary tract carcinoma with variant histology. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2020, 477, 111-120.	2.8	24
215	Molecular pathology of urothelial carcinoma. <i>Human Pathology</i> , 2021, 113, 67-83.	2.0	24
216	Sclerosing Adenosis of the Prostate. <i>Archives of Pathology and Laboratory Medicine</i> , 2003, 127, e14-e16.	2.5	24

#	ARTICLE	IF	CITATIONS
217	Pathology of prostate cancer and focal therapy ('male lumpectomy'). <i>Anticancer Research</i> , 2009, 29, 5155-61.	1.1	24
218	Lymphatic vessel density in radical prostatectomy specimens. <i>Human Pathology</i> , 2008, 39, 610-615.	2.0	23
219	Immunohistochemical Evaluation of Global DNA Methylation and Histone Acetylation in Papillary Urothelial Neoplasm of Low Malignant Potential. <i>International Journal of Immunopathology and Pharmacology</i> , 2008, 21, 615-623.	2.1	23
220	Joint Appraisal of the Radical Prostatectomy Specimen by the Urologist and the Uropathologist: Together, We Can Do It Better. <i>European Urology</i> , 2009, 56, 951-955.	1.9	23
221	Inverted (Endophytic) Noninvasive Lesions and Neoplasms of the Urothelium: The Cinderella Group Has Yet to Be Fully Exploited. <i>European Urology</i> , 2011, 59, 225-230.	1.9	23
222	<i>KRAS</i> mutation is present in a small subset of primary urinary bladder adenocarcinomas. <i>Histopathology</i> , 2012, 61, 1036-1042.	2.9	23
223	Central Prostate Pathology Review: Should It Be Mandatory?. <i>European Urology</i> , 2013, 64, 199-201.	1.9	23
224	Immunoglobulin G4-related Disease in Genitourinary Organs: An Emerging Fibroinflammatory Entity Often Misdiagnosed Preoperatively as Cancer. <i>European Urology</i> , 2013, 64, 865-872.	1.9	23
225	Targeting fibroblast growth factor receptor (FGFR) pathway in renal cell carcinoma. <i>Expert Review of Anticancer Therapy</i> , 2015, 15, 1367-1369.	2.4	23
226	Spectrum of Cystic Epithelial Tumors of the Prostate. <i>American Journal of Surgical Pathology</i> , 2016, 40, 886-895.	3.7	23
227	FGFR3 and Cyclin D3 as urine biomarkers of bladder cancer recurrence. <i>Biomarkers in Medicine</i> , 2016, 10, 243-253.	1.4	23
228	Emerging Molecular Technologies in Renal Cell Carcinoma: Liquid Biopsy. <i>Cancers</i> , 2019, 11, 196.	3.7	23
229	Prediction of Prostatic Involvement by Urothelial Carcinoma in Radical Cystoprostatectomy for Bladder Cancer. <i>Urology</i> , 2009, 74, 385-390.	1.0	22
230	Immunohistochemical Expression and Localization of Somatostatin Receptor Subtypes in Prostate Cancer with Neuroendocrine Differentiation. <i>International Journal of Immunopathology and Pharmacology</i> , 2010, 23, 511-522.	2.1	22
231	Human Papillomavirus is Not an Etiologic Agent of Urothelial Inverted Papillomas. <i>American Journal of Surgical Pathology</i> , 2013, 37, 1223-1228.	3.7	22
232	<i>TERT</i> promoter mutation status in sarcomatoid urothelial carcinomas of the upper urinary tract. <i>Future Oncology</i> , 2017, 13, 705-714.	2.4	22
233	Lymphoepithelioma-like carcinoma of the upper urinary tract. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2017, 470, 703-709.	2.8	22
234	Real-World Data on Cabozantinib in Previously Treated Patients with Metastatic Renal Cell Carcinoma: Focus on Sequences and Prognostic Factors. <i>Cancers</i> , 2020, 12, 84.	3.7	22

#	ARTICLE	IF	CITATIONS
235	Distinct clinicopathological features in metanephric adenoma harboring BRAF mutation. <i>Oncotarget</i> , 2017, 8, 54096-54105.	1.8	22
236	2004 World Health Organization Classification of the Noninvasive Urothelial Neoplasms: Inherent Problems and Clinical Reflections. <i>European Urology Supplements</i> , 2009, 8, 453-457.	0.1	21
237	Atypical Adenomatous Hyperplasia of Prostate Lacks TMPRSS2-ERG Gene Fusion. <i>American Journal of Surgical Pathology</i> , 2013, 37, 1550-1554.	3.7	21
238	Immune Checkpoint Inhibitors in Urothelial Carcinoma: Recommendations for Practical Approaches to PD-L1 and Other Potential Predictive Biomarker Testing. <i>Cancers</i> , 2021, 13, 1424.	3.7	21
239	Atypical Adenomatous Hyperplasia (Adenosis) of the Prostate: DNA Ploidy Analysis and Immunophenotype. <i>International Journal of Surgical Pathology</i> , 2005, 13, 167-173.	0.8	20
240	Histopathology reporting of prostate needle biopsies. 2005 update. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2006, 449, 1-13.	2.8	20
241	Anatomic, morphologic and genetic heterogeneity of prostate cancer: implications for clinical practice. <i>Expert Review of Anticancer Therapy</i> , 2012, 12, 1371-1374.	2.4	20
242	Telomere shortening distinguishes inverted urothelial neoplasms. <i>Histopathology</i> , 2013, 62, 595-601.	2.9	20
243	Clear Cell Renal Cell Carcinoma (ccRCC) with Hemangioblastoma-like Features: A Previously Unreported Pattern of ccRCC with Possible Clinical Significance. <i>European Urology</i> , 2014, 66, 806-810.	1.9	20
244	Emerging Immunotargets in Metastatic Renal Cell Carcinoma. <i>Current Drug Targets</i> , 2016, 17, 771-776.	2.1	20
245	Solitary fibrous tumour of the genitourinary tract: a clinicopathological study of 11 cases and their association with the NAB2-STAT6 fusion gene. <i>Journal of Clinical Pathology</i> , 2017, 70, 508-514.	2.0	20
246	Long Non-coding RNAs in Prostate Cancer with Emphasis on Second Chromosome Locus Associated with Prostate-1 Expression. <i>Frontiers in Oncology</i> , 2017, 7, 305.	2.8	20
247	Recent Advances in Liquid Biopsy in Patients With Castration Resistant Prostate Cancer. <i>Frontiers in Oncology</i> , 2018, 8, 397.	2.8	20
248	Biomarkers of aggressiveness in genitourinary tumors with emphasis on kidney, bladder, and prostate cancer. <i>Expert Review of Molecular Diagnostics</i> , 2018, 18, 645-655.	3.1	20
249	Expression of miR-100 and miR-138 as prognostic biomarkers in non-muscle-invasive bladder cancer. <i>Apmis</i> , 2019, 127, 545-553.	2.0	20
250	Circulating Tumor Cells in Renal Cell Carcinoma: Recent Findings and Future Challenges. <i>Frontiers in Oncology</i> , 2019, 9, 228.	2.8	20
251	Microbiome and Cancers, With Focus on Genitourinary Tumors. <i>Frontiers in Oncology</i> , 2019, 9, 178.	2.8	20
252	International Society of Urological Pathology Expert Opinion on Grading of Urothelial Carcinoma. <i>European Urology Focus</i> , 2022, 8, 438-446.	3.1	20

#	ARTICLE	IF	CITATIONS
253	Ultrastructure of prostatic intraepithelial neoplasia. , 1997, 33, 32-37.		19
254	Molecular characteristics of urothelial neoplasms in children and young adults: a subset of tumors from young patients harbors chromosomal abnormalities but not FGFR3 or TP53 gene mutations. Modern Pathology, 2014, 27, 1540-1548.	5.5	19
255	Seminal Vesicle Intraepithelial Neoplasia Versus Basal Cell Hyperplasia in a Seminal Vesicle. European Urology, 2014, 66, 623-627.	1.9	19
256	Inflammatory myofibroblastic tumour of the urinary bladder: the role of immunoglobulin G4 and the comparison of two immunohistochemical antibodies and fluorescence <i>in situ</i> hybridization for the detection of anaplastic lymphoma kinase alterations. Histopathology, 2015, 67, 20-38.	2.9	19
257	New molecular targets in non clear renal cell carcinoma: An overview of ongoing clinical trials. Cancer Treatment Reviews, 2015, 41, 614-622.	7.7	19
258	Pathology Imagebase™ a reference image database for standardization of pathology. Histopathology, 2017, 71, 677-685.	2.9	19
259	Inherited forms of bladder cancer: a review of Lynch syndrome and other inherited conditions. Future Oncology, 2018, 14, 277-290.	2.4	19
260	Prostate cancer with cribriform morphology: diagnosis, aggressiveness, molecular pathology and possible relationships with intraductal carcinoma. Expert Review of Anticancer Therapy, 2018, 18, 685-693.	2.4	19
261	Metabolic Alterations in Renal and Prostate Cancer. Current Drug Metabolism, 2016, 17, 150-155.	1.2	19
262	Virilizing mature ovarian cystic teratomas. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 1997, 431, 149-151.	2.8	18
263	Apoptotic and proliferation indexes in primary superficial bladder tumors. Cancer Letters, 2006, 242, 266-272.	7.2	18
264	Urethral caruncle: a lesion related to IgG4-associated sclerosing disease?. Journal of Clinical Pathology, 2013, 66, 559-562.	2.0	18
265	Current Histopathologic and Molecular Characterisations of Prostate Cancer: Towards Individualised Prognosis and Therapies. European Urology, 2016, 69, 186-190.	1.9	18
266	Immunohistochemical and molecular characterizations in urothelial carcinoma of bladder in patients less than 45 years. Journal of Cancer, 2017, 8, 323-331.	2.5	18
267	The Expression Patterns of p53 and p16 and an Analysis of a Possible Role of HPV in Primary Adenocarcinoma of the Urinary Bladder. PLoS ONE, 2014, 9, e95724.	2.5	18
268	Bladder Cancer: Molecular Determinants of Personalized Therapy. Current Drug Targets, 2015, 16, 115-124.	2.1	18
269	Cyclin D3 gene amplification in bladder carcinoma in situ. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2010, 457, 555-561.	2.8	17
270	Clonal origin of multifocal hepatocellular carcinoma. Cancer, 2010, 116, 4078-4085.	4.1	17

#	ARTICLE	IF	CITATIONS
271	Primary Renal Osteosarcoma. American Journal of Clinical Pathology, 2014, 141, 747-752.	0.7	17
272	Pseudoangiosarcomatous Urothelial Carcinoma of the Urinary Bladder. American Journal of Surgical Pathology, 2014, 38, 1251-1259.	3.7	17
273	SMARCB1/INI1 Genetic Alterations in Renal Medullary Carcinomas. European Urology, 2016, 69, 1062-1064.	1.9	17
274	Concomitant bladder cancer and prostate cancer: challenges and controversies. Nature Reviews Urology, 2017, 14, 620-629.	3.8	17
275	Immunotherapy in renal cell carcinoma from poverty to the spoiled of choice. Immunotherapy, 2019, 11, 1507-1521.	2.0	17
276	Bicalutamide 50 mg monotherapy in patients with isolated high-grade PIN: findings in repeat biopsies at 6 months. Journal of Clinical Pathology, 2006, 60, 443-446.	2.0	16
277	Stage pT0 in Radical Prostatectomy with No Residual Carcinoma and with a Previous Positive Biopsy Conveys a Wrong Message to Clinicians and Patients: Why Is Cancer Not Present in the Radical Prostatectomy Specimen?. European Urology, 2009, 56, 272-274.	1.9	16
278	Small renal masses in the era of personalized medicine: Tumor heterogeneity, growth kinetics, and risk of metastasis. Urologic Oncology: Seminars and Original Investigations, 2015, 33, 303-309.	1.6	16
279	Update on histopathological evaluation of lymphadenectomy specimens from prostate cancer patients. World Journal of Urology, 2017, 35, 517-526.	2.2	16
280	Variants of Bladder Cancer: The Pathologist's Point of View. European Urology Supplements, 2017, 16, 210-222.	0.1	16
281	Intraoperative Consultation and Macroscopic Handling. American Journal of Surgical Pathology, 2018, 42, e33-e43.	3.7	16
282	Molecular Classification of Bladder Urothelial Carcinoma Using NanoString-Based Gene Expression Analysis. Cancers, 2021, 13, 5500.	3.7	16
283	T-Zone Histiocytes and Recurrence of Papillary Urothelial Bladder Carcinoma. Urologia Internationalis, 1989, 44, 205-209.	1.3	15
284	2005 Update on Pathology of Prostate Biopsies with Cancer. European Urology, 2006, 49, 441-447.	1.9	15
285	Immunohistochemical Expression of Prostate Stem Cell Antigen in Cystoprostatectomies with Incidental Prostate Cancer. International Journal of Immunopathology and Pharmacology, 2009, 22, 755-762.	2.1	15
286	Expression of prostate stem cell antigen in high-grade prostatic intraepithelial neoplasia and prostate cancer. Histopathology, 2010, 57, 572-579.	2.9	15
287	Evidence for clonal fibroblast proliferation and autoimmune process in idiopathic retroperitoneal fibrosis. Human Pathology, 2012, 43, 1875-1880.	2.0	15
288	Iatrogenic pathology of the urinary bladder. Seminars in Diagnostic Pathology, 2018, 35, 218-227.	1.5	15

#	ARTICLE	IF	CITATIONS
289	Hypochromatic large urothelial cells in urine cytology are indicative of high grade urothelial carcinoma. <i>Apmis</i> , 2018, 126, 705-709.	2.0	15
290	Key Role of Obesity in Genitourinary Tumors with Emphasis on Urothelial and Prostate Cancers. <i>Cancers</i> , 2019, 11, 1225.	3.7	15
291	T1 bladder carcinoma with variant histology: pathological features and clinical significance. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2022, 480, 989-998.	2.8	15
292	P53 expression in small cell carcinoma of the urinary bladder: biological and prognostic implications. <i>Anticancer Research</i> , 2005, 25, 2001-4.	1.1	15
293	The pathology of bladder cancer: an update on selected issues. <i>BJU International</i> , 2006, 98, 1161-1165.	2.5	14
294	PATHOLOGICAL DEFINITION AND DIFFICULTIES IN ASSESSING POSITIVE MARGINS IN RADICAL PROSTATECTOMY SPECIMENS. <i>BJU International</i> , 2009, 103, 286-288.	2.5	14
295	Immunohistochemical expression of prostate tumor overexpressed 1 in cystoprostatectomies with incidental and insignificant prostate cancer.. <i>Human Pathology</i> , 2011, 42, 1931-1936.	2.0	14
296	Handling of radical prostatectomy specimens: total embedding with whole mounts, with special reference to the Ancona experience. <i>Histopathology</i> , 2011, 59, 1006-1010.	2.9	14
297	Nest-Like Features in Bladder, Simulating the Nested Variant of Urothelial Carcinoma. <i>International Journal of Surgical Pathology</i> , 2011, 19, 11-19.	0.8	14
298	Immunohistochemical expression of prostate tumour overexpressed 1 (PTOV1) in atypical adenomatous hyperplasia (AAH) of the prostate. <i>Cellular Oncology (Dordrecht)</i> , 2013, 36, 37-42.	4.4	14
299	Re: Multilocular Cystic Renal Cell Carcinoma with Focus on Clinical and Pathobiological Aspects. <i>European Urology</i> , 2013, 63, 400-401.	1.9	14
300	Genito-urinary genomics and emerging biomarkers for immunomodulatory cancer treatment. <i>Seminars in Cancer Biology</i> , 2018, 52, 216-227.	9.6	14
301	Predictive biomarkers for immunotherapy in the treatment of advanced urothelial carcinoma: where we stand and where we go. <i>Future Oncology</i> , 2019, 15, 2199-2202.	2.4	14
302	Data set for the reporting of carcinoma of renal tubular origin: recommendations from the International Collaboration on Cancer Reporting (<scp>ICCR</scp>). <i>Histopathology</i> , 2019, 74, 377-390.	2.9	14
303	Liquid biopsy in the clinical management of bladder cancer: current status and future developments. <i>Expert Review of Molecular Diagnostics</i> , 2020, 20, 255-264.	3.1	14
304	Molecular characterization and diagnostic criteria of renal cell carcinoma with emphasis on liquid biopsies. <i>Expert Review of Molecular Diagnostics</i> , 2020, 20, 141-150.	3.1	14
305	Combination therapy in advanced urothelial cancer: the role of PARP, HER-2 and mTOR inhibitors. <i>Expert Review of Anticancer Therapy</i> , 2020, 20, 755-763.	2.4	14
306	Epigenetic Modifications and Modulators in Prostate Cancer. <i>Critical Reviews in Oncogenesis</i> , 2017, 22, 439-450.	0.4	14

#	ARTICLE	IF	CITATIONS
307	Evaluation of Prognostic Factors in Radical Prostatectomy Specimens with Cancer. <i>Urologia Internationalis</i> , 2002, 68, 209-215.	1.3	13
308	Association of human herpesvirus type 6 DNA with human bladder cancer. <i>Cancer Letters</i> , 2005, 230, 20-24.	7.2	13
309	Extent of Cancer of Less Than 50% in Any Prostate Needle Biopsy Core: How Many Millimeters Are There?. <i>European Urology</i> , 2012, 61, 751-756.	1.9	13
310	Pathology of Upper Tract Urothelial Carcinoma with Emphasis on Staging. <i>International Journal of Immunopathology and Pharmacology</i> , 2014, 27, 509-516.	2.1	13
311	Renal cell carcinoma with rhabdoid features and loss of INI1 expression in an individual without sickle cell trait. <i>Pathology</i> , 2014, 46, 653-655.	0.6	13
312	Unlike in clear cell renal cell carcinoma, KRAS is not mutated in multilocular cystic clear cell renal cell neoplasm of low potential. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2015, 467, 687-693.	2.8	13
313	Whole Slide Imaging of Large Format Histology in Prostate Pathology: Potential for Information Fusion. <i>Archives of Pathology and Laboratory Medicine</i> , 2017, 141, 1460-1461.	2.5	13
314	MYB-NFIB gene fusion in prostatic basal cell carcinoma: clinicopathologic correlates and comparison with basal cell adenoma and florid basal cell hyperplasia. <i>Modern Pathology</i> , 2019, 32, 1666-1674.	5.5	13
315	Intraductal Carcinoma of the Prostate: Pathogenesis and Molecular Perspectives. <i>European Urology Focus</i> , 2021, 7, 955-963.	3.1	13
316	An update on investigational therapies that target STAT3 for the treatment of cancer. <i>Expert Opinion on Investigational Drugs</i> , 2021, 30, 245-251.	4.1	13
317	An Overview of Emerging Immunotargets of Genitourinary Tumors. <i>Current Drug Targets</i> , 2016, 17, 750-756.	2.1	13
318	Towards personalized therapy for patients with malignant melanoma: molecular insights into the biology of BRAF mutations. <i>Future Oncology</i> , 2013, 9, 245-253.	2.4	12
319	EGFR alterations and EML4-ALK rearrangement in primary adenocarcinoma of the urinary bladder. <i>Modern Pathology</i> , 2014, 27, 107-112.	5.5	12
320	Genetic mutations in accordance with a low malignant potential tumour are not demonstrated in clear cell papillary renal cell carcinoma. <i>Journal of Clinical Pathology</i> , 2016, 69, 547-550.	2.0	12
321	Circulating Tumor DNA Testing for Homology Recombination Repair Genes in Prostate Cancer: From the Lab to the Clinic. <i>International Journal of Molecular Sciences</i> , 2021, 22, 5522.	4.1	12
322	PD1 and PD-L1 Inhibitors for the Treatment of Kidney Cancer: The Role of PD-L1 Assay. <i>Current Drug Targets</i> , 2020, 21, 1664-1671.	2.1	12
323	Morphological and molecular profiles and pathways in bladder neoplasms. <i>Anticancer Research</i> , 2008, 28, 2893-900.	1.1	12
324	Biological and clinical perspectives of TERT promoter mutation detection on bladder cancer diagnosis and management. <i>Human Pathology</i> , 2023, 133, 56-75.	2.0	12

#	ARTICLE	IF	CITATIONS
325	Immunohistochemical expression of somatostatin receptor subtypes in prostate tissue from cystoprostatectomies with incidental prostate cancer. <i>BJU International</i> , 2010, 106, 1072-1080.	2.5	11
326	Is There a Role for Prostate Tumour Overexpressed-1 in the Diagnosis of HGPIN and of Prostatic Adenocarcinoma? A Comparison with \pm -Methylacyl CoA Racemase. <i>International Journal of Immunopathology and Pharmacology</i> , 2012, 25, 67-74.	2.1	11
327	Immunohistochemical analysis of chromatin remodeler DAXX in high grade urothelial carcinoma. <i>Diagnostic Pathology</i> , 2013, 8, 111.	2.0	11
328	Testing PD-1/PD-L1 Expression in Cancer Therapy: Pathologic Insights and Economic Sustainability. <i>Archives of Pathology and Laboratory Medicine</i> , 2016, 140, 501-502.	2.5	11
329	Germline and somatic mutations in prostate cancer: focus on defective DNA repair, PARP inhibitors and immunotherapy. <i>Future Oncology</i> , 2020, 16, 75-80.	2.4	11
330	Stage T1 bladder cancer: diagnostic criteria and pitfalls. <i>Pathology</i> , 2021, 53, 67-85.	0.6	11
331	Added Clinical Value of Whole-mount Histopathology of Radical Prostatectomy Specimens: A Collaborative Review. <i>European Urology Oncology</i> , 2021, 4, 558-569.	5.4	11
332	Genitourinary Tumors: Update on Molecular Biomarkers for Diagnosis, Prognosis and Prediction of Response to Therapy. <i>Current Drug Metabolism</i> , 2019, 20, 305-312.	1.2	11
333	Morphologic and Molecular Backgrounds for Personalized Management of Genito-Urinary Cancers: An Overview. <i>Current Drug Targets</i> , 2015, 16, 96-102.	2.1	11
334	Expression of P-glycoprotein and metallothionein in gastrointestinal stromal tumor and leiomyosarcomas. Clinical implications. <i>Pathology and Oncology Research</i> , 2007, 13, 203-208.	1.9	10
335	Decision support systems for morphology-based diagnosis and prognosis of prostate neoplasms. <i>Cancer</i> , 2009, 115, 3068-3077.	4.1	10
336	Genetic profiles in renal tumors. <i>International Journal of Urology</i> , 2010, 17, 6-19.	1.0	10
337	Does prostate acinar adenocarcinoma with Gleason Score 3 + 3 = 6 have the potential to metastasize?. <i>Diagnostic Pathology</i> , 2014, 9, 190.	2.0	10
338	Total submission of lymphadenectomy tissues removed during radical prostatectomy for prostate cancer: possible clinical significance of large-format histology. <i>Human Pathology</i> , 2014, 45, 2059-2062.	2.0	10
339	Re: Epithelial-to-mesenchymal Transition in Renal Neoplasms. <i>European Urology</i> , 2015, 68, 736-737.	1.9	10
340	Present and future of personalized medicine in adult genitourinary tumors. <i>Future Oncology</i> , 2015, 11, 1381-1388.	2.4	10
341	A contemporary series of renal masses with emphasis on recently recognized entities and tumors of low malignant potential: A report based on 624 consecutive tumors from a single tertiary center. <i>Pathology Research and Practice</i> , 2017, 213, 804-808.	2.3	10
342	Oligometastases in Genitourinary Tumors: Recent Insights and Future Molecular Diagnostic Approach. <i>European Urology Supplements</i> , 2017, 16, 309-315.	0.1	10

#	ARTICLE	IF	CITATIONS
343	Cytological and histological changes in the urothelium produced by electromotive drug administration (EMDA) and by the combination of intravesical hyperthermia and chemotherapy (thermochemotherapy). <i>Pathology Research and Practice</i> , 2017, 213, 1078-1081.	2.3	10
344	Emerging immunotherapeutic strategies targeting telomerases in genitourinary tumors. <i>Critical Reviews in Oncology/Hematology</i> , 2018, 131, 1-6.	4.4	10
345	Prostate cancer grading in 2018: limitations, implementations, cribriform morphology, and biological markers. <i>International Journal of Biological Markers</i> , 2018, 33, 331-334.	1.8	10
346	Narrative review of prostate cancer grading systems: will the Gleason scores be replaced by the Grade Groups?. <i>Translational Andrology and Urology</i> , 2021, 10, 1530-1540.	1.4	10
347	Emerging Immunotargets and Immunotherapies in Prostate Cancer. <i>Current Drug Targets</i> , 2016, 17, 777-782.	2.1	10
348	Immunotherapy and Radiation Therapy in Renal Cell Carcinoma. <i>Current Drug Targets</i> , 2020, 21, 1463-1475.	2.1	10
349	Evolution of extramedullary plasmacytoma in a patient with primary Sjögren's syndrome. <i>Arthritis and Rheumatism</i> , 1990, 33, 150-151.	6.7	9
350	Expression of OCT4 Transcription Factor in Cutaneous Neoplasia. <i>Applied Immunohistochemistry and Molecular Morphology</i> , 2007, 15, 359-362.	1.2	9
351	Renal oncocytosis and multiple papillary adenomas with oncocytoma as dominant nodule coexisting with papillary carcinoma in a patient with diabetic glomerulosclerosis, acquired renal cystic disease and B cell lymphoma. <i>Apmis</i> , 2008, 116, 934-938.	2.0	9
352	Targeted therapies and biological modifiers in urologic tumors: pathobiology and clinical implications. <i>Seminars in Diagnostic Pathology</i> , 2008, 25, 232-244.	1.5	9
353	How much do you know about benign, preneoplastic, non-invasive and invasive neoplastic lesions of the urinary bladder classified according to the 2004 WHO scheme?. <i>Diagnostic Pathology</i> , 2011, 6, 31.	2.0	9
354	The Importance of Interaction Between Urologists and Pathologists in Incidental Prostate Cancer Management. <i>European Urology</i> , 2011, 60, 75-77.	1.9	9
355	Pathology and molecular updates in tumors of the prostate: towards a personalized approach. <i>Expert Review of Molecular Diagnostics</i> , 2017, 17, 781-789.	3.1	9
356	Digital versus light microscopy assessment of surgical margin status after radical prostatectomy. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2018, 472, 451-460.	2.8	9
357	Another one in the chamber: cabozantinib for patients with metastatic non clear cell renal cell carcinoma. <i>Annals of Translational Medicine</i> , 2019, 7, S137-S137.	1.7	9
358	Immunotherapy for urothelial cancer: from the diagnostic pathologist's point of view. <i>Expert Opinion on Biological Therapy</i> , 2020, 20, 539-544.	3.1	9
359	Telomerase reverse transcriptase (TERT) promoter mutations in primary adenocarcinoma of bladder and urothelial carcinoma with glandular differentiation: pathogenesis and diagnostic implications. <i>Modern Pathology</i> , 2021, 34, 1384-1391.	5.5	9
360	Prostate Cancer in 2021: Novelties in Prognostic and Therapeutic Biomarker Evaluation. <i>Cancers</i> , 2021, 13, 3471.	3.7	9

#	ARTICLE	IF	CITATIONS
361	Emerging Immunotargets in Bladder Cancer. <i>Current Drug Targets</i> , 2016, 17, 757-770.	2.1	9
362	Pathology of renal cell carcinoma: an update. <i>Analytical and Quantitative Cytopathology and Histopathology</i> , 2013, 35, 61-76.	0.2	9
363	The dilemma of multiorgan donors with high serum PSA—a pathologist's proposal. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2006, 449, 273-276.	2.8	8
364	Clonality and TP53 Mutation Analysis of Focal Nodular Hyperplasia of the Liver. <i>American Journal of Clinical Pathology</i> , 2010, 134, 65-70.	0.7	8
365	Cervical-type Squamous Metaplasia and Myoepithelial Cell Differentiation in Stromal Tumor of the Prostate. <i>American Journal of Surgical Pathology</i> , 2011, 35, 1752-1754.	3.7	8
366	Immunohistochemical expression and localization of somatostatin receptor subtypes in androgen ablated prostate cancer. <i>Cellular Oncology (Dordrecht)</i> , 2011, 34, 235-243.	4.4	8
367	Combined handling of prostate base/bladder neck and seminal vesicles in radical prostatectomy specimens: our approach with the whole mount technique. <i>Histopathology</i> , 2013, 63, 431-435.	2.9	8
368	A Better Understanding of the Morphological Features and Molecular Characteristics of Intraductal Carcinoma Helps Clinicians Further Explain Prostate Cancer Aggressiveness. <i>European Urology</i> , 2015, 67, 504-507.	1.9	8
369	Quantitative Image Analysis on Histologic Virtual Slides for Prostate Pathology Diagnosis, Response to Chemopreventive Agents, and Prognosis. <i>European Urology Focus</i> , 2017, 3, 467-469.	3.1	8
370	Upper urinary tract urothelial carcinoma and its variants: transition from morphology to personalized molecular characterization in diagnosis, prognosis, and therapy. <i>Expert Review of Molecular Diagnostics</i> , 2018, 18, 1021-1028.	3.1	8
371	Histopathologic challenges: The second OPINION issue. <i>European Journal of Surgical Oncology</i> , 2019, 45, 12-15.	1.0	8
372	Urologists During the COVID-19 Pandemic: What Can Be Learned in Terms of Social Interaction, Visibility, and Social Distance. <i>European Urology</i> , 2020, 78, 478-481.	1.9	8
373	Update on Circulating Tumor Cells in Genitourinary Tumors with Focus on Prostate Cancer. <i>Cells</i> , 2020, 9, 1495.	4.1	8
374	pT1 high-grade bladder cancer: histologic criteria, pitfalls in the assessment of invasion, and substaging. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2020, 477, 3-16.	2.8	8
375	Predicting future cancer burden in the United States by artificial neural networks. <i>Future Oncology</i> , 2021, 17, 159-168.	2.4	8
376	Prognostic microRNAs in upper tract urothelial carcinoma: multicenter and international validation study. <i>Oncotarget</i> , 2017, 8, 51522-51529.	1.8	8
377	Human papillomavirus (HPV)-induced neoplasia in the urinary bladder: a missing link?. <i>Histology and Histopathology</i> , 2016, 31, 595-600.	0.7	8
378	Small cell carcinoma of the prostate: molecular basis and clinical implications. <i>Histology and Histopathology</i> , 2015, 30, 413-24.	0.7	8

#	ARTICLE	IF	CITATIONS
379	Global Acetylation and Methylation Changes Predict Papillary Urothelial Neoplasia of Low Malignant Potential Recurrence: A Quantitative Analysis. <i>International Journal of Immunopathology and Pharmacology</i> , 2011, 24, 489-497.	2.1	7
380	Editorial Comment to When should we expect no residual tumor (pT0) once we submit incidental T1aâ€b prostate cancers to radical prostatectomy?. <i>International Journal of Urology</i> , 2011, 18, 153-154.	1.0	7
381	A Contemporary Update and Pathology Reporting for Urinary Bladder Cancer. <i>International Journal of Immunopathology and Pharmacology</i> , 2012, 25, 565-571.	2.1	7
382	Lymphocytic vasculitis of the prostate transition zone. <i>BJU International</i> , 2012, 110, 1775-1780.	2.5	7
383	Treatment Effects in Prostate Cancer following Traditional and Emerging Therapies. <i>International Journal of Immunopathology and Pharmacology</i> , 2013, 26, 291-298.	2.1	7
384	A low grade PIN-like neoplasm of the transition zone immunohistochemically negative for basal cell markers: a possible example of low grade adenocarcinoma with stratified epithelium. <i>Pathology</i> , 2014, 46, 88-91.	0.6	7
385	Urinary bladder xanthoma: a multiâ€institutional series of 17 cases. <i>Histopathology</i> , 2015, 67, 255-261.	2.9	7
386	Pseudocarcinomatous hyperplasia associated with primary lymphoma in the urinary bladder: a case report. <i>Human Pathology</i> , 2015, 46, 1040-1044.	2.0	7
387	Contemporary best practice in the management of urothelial carcinomas of the renal pelvis and ureter. <i>Therapeutic Advances in Urology</i> , 2019, 11, 175628721881537.	2.0	7
388	A Multiplex Test Assessing MiR663ame and VIMme in Urine Accurately Discriminates Bladder Cancer from Inflammatory Conditions. <i>Journal of Clinical Medicine</i> , 2020, 9, 605.	2.4	7
389	Somatostatin receptor subtypes in hormone-refractory (castration-resistant) prostatic carcinoma. <i>Asian Journal of Andrology</i> , 2011, 13, 242-247.	1.6	7
390	Immunohistochemical Expression and Localization of Somatostatin Receptor Subtypes in Androgen Ablated Prostate Cancer. <i>Analytical Cellular Pathology</i> , 2010, 33, 27-36.	1.4	7
391	Liquid Biopsies in the Management of Bladder Cancer: Next-Generation Biomarkers for Diagnosis, Surveillance, and Treatment-Response Prediction. <i>Critical Reviews in Oncogenesis</i> , 2017, 22, 389-401.	0.4	7
392	Circulating Tumor Cells: A Reliable Biomarker for Prostate Cancer Treatment Assessment?. <i>Current Drug Metabolism</i> , 2017, 18, 692-699.	1.2	7
393	Urothelial dysplasia of the bladder: diagnostic features and clinical significance. <i>Analytical and Quantitative Cytopathology and Histopathology</i> , 2013, 35, 121-9.	0.2	7
394	Recurrent papillary urothelial neoplasm of low malignant potential. Subtle architectural disorder detected by quantitative analysis in DAXX-immunostained tissue sections. <i>Human Pathology</i> , 2014, 45, 745-752.	2.0	6
395	Multiple and bilateral kidney tumors with clear cells of three different histotypes: A case report with clinicopathologic and molecular study. <i>Apmis</i> , 2016, 124, 619-623.	2.0	6
396	Immunotargeting and personalized therapies in genitourinary cancers. <i>Future Oncology</i> , 2016, 12, 1853-1856.	2.4	6

#	ARTICLE	IF	CITATIONS
397	Re: Daniel M. Geynisman. Anti-programmed Cell Death Protein 1 (PD-1) Antibody Nivolumab Leads to a Dramatic and Rapid Response in Papillary Renal Cell Carcinoma with Sarcomatoid and Rhabdoid Features. <i>Eur Urol</i> 2015;68:912-4. <i>European Urology</i> , 2016, 70, e72-e74.	1.9	6
398	Activity and Functions of Tumor-associated Macrophages in Prostate Carcinogenesis. <i>European Urology Supplements</i> , 2017, 16, 301-308.	0.1	6
399	<i>TMPRSS2-ERG</i> gene fusion is rare compared to <i>PTEN</i> deletions in stage T1a prostate cancer. <i>Molecular Carcinogenesis</i> , 2017, 56, 814-820.	2.7	6
400	Re: Karim A. Touijer, James A. Eastham. The Sentinel Lymph Node Concept and Novel Approaches in Detecting Lymph Node Metastasis in Prostate Cancer. <i>Eur Urol</i> 2016;70:738-9. <i>European Urology</i> , 2017, 71, e73-e75.	1.9	6
401	Intratumoural heterogeneity may hinder precision medicine strategies in patients with clear cell renal cell carcinoma. <i>Journal of Clinical Pathology</i> , 2018, 71, 467-471.	2.0	6
402	Biological issues with cabozantinib in bone metastatic renal cell carcinoma and castration-resistant prostate cancer. <i>Future Oncology</i> , 2018, 14, 2559-2564.	2.4	6
403	Re: Gillian Vandekerkhove, Werner J. Struss, Matti Annala, et al. Circulating Tumor DNA Abundance and Potential Utility in De Novo Metastatic Prostate Cancer. <i>Eur Urol</i> 2019;75:667-75. <i>European Urology</i> , 2019, 76, e69-e72.	1.9	6
404	Prostate cancer pathology: What has changed in the last 5 years. <i>Urologia</i> , 2020, 87, 3-10.	0.7	6
405	Designing novel immunocombinations in metastatic renal cell carcinoma. <i>Immunotherapy</i> , 2020, 12, 1257-1268.	2.0	6
406	New Frontiers in Prostate Cancer Treatment: Are We Ready for Drug Combinations with Novel Agents?. <i>Cells</i> , 2020, 9, 1522.	4.1	6
407	Digital diagnostics and artificial intelligence in prostate cancer treatment in 5 years from now. <i>Translational Andrology and Urology</i> , 2021, 10, 1499-1505.	1.4	6
408	Molecular Characterization of Testicular Germ Cell Tumors Using Tissue Microdissection. <i>Methods in Molecular Biology</i> , 2021, 2195, 31-47.	0.9	6
409	Radical prostatectomy specimen processing: A critical appraisal of sampling methods. <i>Current Diagnostic Pathology</i> , 2007, 13, 490-498.	0.4	5
410	Splitting and Lumping Adult Renal Epithelial Tumours: Is That What the Urologists Want?. <i>European Urology</i> , 2008, 53, 673-675.	1.9	5
411	Re: Peripheral Zone Prostate Cancers: Location and Intraprostatic Patterns of Spread at Histopathology. <i>European Urology</i> , 2010, 58, 180-182.	1.9	5
412	Re: Antibody-drug Conjugates Targeting Prostate-specific Membrane Antigen. <i>European Urology</i> , 2014, 66, 1190-1193.	1.9	5
413	Precision medicine in colorectal cancer: evolving genomic landscape and emerging consensus. <i>Future Oncology</i> , 2015, 11, 2711-2719.	2.4	5
414	Prostate cancer glands with cribriform architecture and with glomeruloid features should be considered as Gleason pattern 4 and not pattern 3. <i>Future Oncology</i> , 2016, 12, 1431-1433.	2.4	5

#	ARTICLE	IF	CITATIONS
415	Müllerian Adenosarcoma of the Urinary Bladder: Clinicopathologic and Immunohistochemical Features With Novel Genetic Aberrations. <i>Clinical Genitourinary Cancer</i> , 2017, 15, e1007-e1014.	1.9	5
416	From Gleason Grading System and High-grade Tertiary Patterns to Grade Groups and Integrated Quantitative Gleason Score. <i>European Urology</i> , 2018, 73, 684-686.	1.9	5
417	Molecular evidence supporting the precursor nature of atypical adenomatous hyperplasia of the prostate. <i>Molecular Carcinogenesis</i> , 2019, 58, 1272-1278.	2.7	5
418	Data Set for the Reporting of Carcinoma of the Renal Pelvis and Ureter—Nephroureterectomy and Ureterectomy Specimens. <i>American Journal of Surgical Pathology</i> , 2019, 43, e1-e12.	3.7	5
419	Liquid biopsies in urological cancers: what we need to know before starting using them. <i>Expert Review of Molecular Diagnostics</i> , 2020, 20, 135-139.	3.1	5
420	An evaluation of current prostate cancer diagnostic approaches with emphasis on liquid biopsies and prostate cancer. <i>Expert Review of Molecular Diagnostics</i> , 2020, 20, 207-217.	3.1	5
421	Chromophobe Renal Cell Carcinoma Aggressiveness and Immuno-oncology Therapy: How to Distinguish the Good One from the Bad One. <i>European Urology Oncology</i> , 2021, 4, 331-333.	5.4	5
422	Fluorescence In Situ Hybridization (FISH) Detection of Chromosomal 12p Anomalies in Testicular Germ Cell Tumors. <i>Methods in Molecular Biology</i> , 2021, 2195, 49-63.	0.9	5
423	Mesonephric (Wolffian-derived) Adenocarcinoma of the Female Urethra. <i>American Journal of Surgical Pathology</i> , 2021, 45, 543-549.	3.7	5
424	Active surveillance for low-risk prostate cancer. <i>Anticancer Research</i> , 2010, 30, 3683-92.	1.1	5
425	Vasculitis Involving the Prostate. , 1996, 1, 70-73.		4
426	Macrocryosectioning and complete sampling of the prostate in a potential multiorgan donor candidate. <i>Journal of Clinical Pathology</i> , 2006, 60, 951-952.	2.0	4
427	Pathological Reflection on European Urology: Extended, Saturation, and Systematic Prostate Biopsies. <i>European Urology</i> , 2008, 53, 1111-1114.	1.9	4
428	Pathology of flat bladder lesions with emphasis on putative precursors. <i>Diagnostic Histopathology</i> , 2013, 19, 355-365.	0.4	4
429	Somatostatin receptor expression in prostate carcinoma: the urological pathologist's role in the era of personalised medicine. <i>Pathology</i> , 2013, 45, 93-96.	0.6	4
430	Editorial (Thematic Issue: Emerging Immunotargets in Genitourinary Tumors). <i>Current Drug Targets</i> , 2016, 17, 748-749.	2.1	4
431	Clinical impact of tumoral angiogenesis on renal cell carcinoma management: where do we stand?. <i>Expert Review of Precision Medicine and Drug Development</i> , 2016, 1, 229-231.	0.7	4
432	Activity of chemokines in prostate and renal tumors and their potential role as future therapeutic targets. <i>Future Oncology</i> , 2017, 13, 1105-1114.	2.4	4

#	ARTICLE	IF	CITATIONS
433	Morphologic Variants of Epithelial and Neuroendocrine Tumors of the Prostate. The Pathologist's Point of View. <i>European Urology Supplements</i> , 2017, 16, 223-231.	0.1	4
434	Editorial: Emerging Biomarkers in Genitourinary Tumors. <i>Frontiers in Oncology</i> , 2019, 9, 326.	2.8	4
435	Dataset for the reporting of renal biopsy for tumour: recommendations from the International Collaboration on Cancer Reporting (ICCR). <i>Journal of Clinical Pathology</i> , 2019, 72, 573-578.	2.0	4
436	Re: Multi-institutional Re-evaluation of Prognostic Factors in Chromophobe Renal Cell Carcinoma: Proposal of a Novel Two-tiered Grading Scheme. <i>European Urology</i> , 2020, 78, 114-116.	1.9	4
437	Molecular diagnostics in uro-oncology. <i>Expert Review of Molecular Diagnostics</i> , 2020, 20, 117-121.	3.1	4
438	Exciting experiences in the "Rocky road to digital diagnostics". <i>Journal of Clinical Pathology</i> , 2021, 74, 5-6.	2.0	4
439	Workgroup 5: Assessment of prostate carcinoma in core needle biopsy—Definition of minimal criteria for the diagnosis of cancer in biopsy material. <i>Cancer</i> , 1996, 78, 376-381.	4.1	4
440	Implications of Cancer Stem Cells for Cancer Therapy. , 2009, , 255-262.		4
441	Update on Prostate Cancer Diagnosis, Prognosis, and Prediction to Response to Therapy. <i>Cells</i> , 2021, 10, 20.	4.1	4
442	Immunohistochemical expression and localization of somatostatin receptor subtypes in androgen ablated prostate cancer. <i>Analytical Cellular Pathology</i> , 2010, 33, 27-36.	1.4	4
443	Editorial Comment on: Expression of the Endothelin Axis in Noninvasive and Superficially Invasive Bladder Cancer: Relation to Clinicopathologic and Molecular Prognostic Parameters. <i>European Urology</i> , 2009, 56, 846-847.	1.9	3
444	The Gleason grading system: where are we now?. <i>Diagnostic Histopathology</i> , 2011, 17, 419-427.	0.4	3
445	Synchronous Metastasis From Lobular Carcinoma and Primary Carcinoma of the Endometrium in a Patient After Tamoxifen Therapy. <i>International Journal of Gynecological Pathology</i> , 2013, 32, 66-70.	1.4	3
446	Prostate changes related to therapy: with special reference to hormone therapy. <i>Future Oncology</i> , 2014, 10, 1873-1886.	2.4	3
447	Rare Tumors and Tumor-like Conditions in Urological Pathology. , 2015, , .		3
448	Considerations for standardizing predictive molecular pathology for cancer prognosis. <i>Expert Review of Molecular Diagnostics</i> , 2017, 17, 47-55.	3.1	3
449	Variants and Variations in Epithelial Renal Cell Tumors in Adults: The Pathologist's Point of View. <i>European Urology Supplements</i> , 2017, 16, 232-240.	0.1	3
450	Re: Isabel Rauscher, Charlotte DÃ¶wle, Bernhard Haller, et al. Efficacy, Predictive Factors, and Prediction Nomograms for 68Ga-labeled Prostate-specific Membrane Antigenâ€“ligand Positron-emission Tomography/Computed Tomography in Early Biochemical Recurrent Prostate Cancer After Radical Prostatectomy. <i>Eur Urol</i> 2018;73:656â€“61. <i>European Urology</i> , 2018, 74, e141-e144.	1.9	3

#	ARTICLE	IF	CITATIONS
451	Prostate Cancer Grading: Are We Heading Towards Grade Grouping Version 2?. <i>European Urology</i> , 2019, 75, 32-34.	1.9	3
452	Predicting biochemical recurrence after radical prostatectomy: the role of prognostic grade group and index tumor nodule. <i>Human Pathology</i> , 2019, 93, 6-15.	2.0	3
453	Digital versus light microscopy assessment of extraprostatic extension in radical prostatectomy samples. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2019, 475, 735-744.	2.8	3
454	Dataset for reporting of carcinoma of the urethra (in urethrectomy specimens): recommendations from the International Collaboration on Cancer Reporting (ICCR). <i>Histopathology</i> , 2019, 75, 453-467.	2.9	3
455	Targeted therapy for solid tumors and risk of hypertension: a meta-analysis of 68077 patients from 93 phase III studies. <i>Expert Review of Cardiovascular Therapy</i> , 2019, 17, 917-927.	1.5	3
456	Re: Friederike Haidl, David Pfister, Axel Heidenreich. Re: Prostatic Artery Embolization in the Treatment of Localized Prostate Cancer: A Bicentric Prospective Proof-of-Concept Study of 12 Patients. Mordasini L, Hechelhammer L, Diener PA, et al. <i>J Vasc Interv Radiol</i> 2018;29:589-97. <i>Eur Urol</i> 2018;74:525-6. <i>European Urology</i> , 2019, 75, e110-e113.	1.9	3
457	Neoplasms of the Urinary Bladder. , 2020, , 230-321.e19.		3
458	Adjuvant therapy in renal cell carcinoma: is it the right strategy to inhibit VEGF?. <i>Translational Andrology and Urology</i> , 2021, 10, 1581-1587.	1.4	3
459	Urinary Biomarkers for Prostate Cancer. <i>Current Drug Metabolism</i> , 2017, 18, 723-726.	1.2	3
460	Extramammary Paget disease of the penis closely mimicking the penile analogue of stratified mucin-producing intraepithelial lesion. <i>Minerva Urologica E Nefrologica = the Italian Journal of Urology and Nephrology</i> , 2019, 71, 189-190.	3.9	3
461	Chromosomal abnormalities in macroscopically normal urothelium in patients with bladder pT1 and pT2a urothelial carcinoma: a fluorescence in situ hybridization study and correlation with histologic features. , 2005, 27, 143-51.		3
462	The European Network of Uropathology: a novel mechanism for communication between pathologists. , 2009, 31, 90-5.		3
463	Cell proliferation and apoptosis in prostate needle biopsies with adenocarcinoma Gleason score 6 or 7. , 2012, 34, 61-5.		3
464	Editorial Comment on: Prediction of Progression of Non-Muscle-Invasive Bladder Cancer by WHO 1973 and 2004 Grading and by FGFR3 Mutation Status: A Prospective Study. <i>European Urology</i> , 2008, 54, 843-844.	1.9	2
465	Urothelial Dysplasia and Its Mimics. , 2008, 13, 149-153.		2
466	Rare Lesions and Tumors of the Urinary Bladder. <i>Selected Issues. Tumori</i> , 2012, 98, 274-277.	1.1	2
467	Precise Morphologic Documentation with Large-format Histology of Clinical Findings in a Bladder Cancer Patient. <i>European Urology</i> , 2013, 64, 519-521.	1.9	2
468	Pathological issues in biopsy specimens of men with prostate cancer eligible for active surveillance. <i>Archivio Italiano Di Urologia Andrologia</i> , 2014, 86, 314.	0.8	2

#	ARTICLE	IF	CITATIONS
469	Normal cystoscopy, malignant cytology in NMIBC: why biopsy?. <i>Nature Reviews Urology</i> , 2014, 11, 550-551.	3.8	2
470	Genitourinary Cancers: Molecular Determinants for Personalized Therapies. <i>Urologia</i> , 2016, 83, 107-109.	0.7	2
471	Synchronous clear cell renal cell carcinoma and multilocular cystic renal cell neoplasia of low malignant potential: A clinico-pathologic and molecular study. <i>Pathology Research and Practice</i> , 2016, 212, 471-474.	2.3	2
472	Intracardiac leiomyomatosis presenting as an intraoperative consultation. <i>Pathology Research and Practice</i> , 2016, 212, 578-581.	2.3	2
473	Re: Kenneth A. Iczkowski's Letter to the Editor re: Re: Rodolfo Montironi, Silvia Gasparini, Roberta Mazzucchelli, et al's Letter to the Editor re: Karim A. Touijer, James A. Eastham. The Sentinel Lymph Node Concept and Novel Approaches in Detecting Lymph Node Metastasis in Prostate Cancer. <i>Eur Urol</i> 2016;70:738-740; Sentinel Lymph Nodes in Adipose Tissue Surrounding the Prostate Gland and Seminal Vesicles as Observed in Virtual Whole-mount Histologic Slides. <i>Eur Urol</i> 2017;71:e73-75. <i>European Urology</i> , 2017, 72, e37-e38.	1.9	2
474	Immunotherapy in genitourinary cancers: where are we going?. <i>Expert Review of Precision Medicine and Drug Development</i> , 2017, 2, 73-78.	0.7	2
475	Editorial: Emerging Biomarkers in Genitourinary Tumors. <i>Current Drug Metabolism</i> , 2017, 18, 690-691.	1.2	2
476	Re: Maud Rijnders, Astrid A.M. van der Veldt, Tahlita C.M. Zuiverloon, et al. PD-L1 Antibody Comparison in Urothelial Carcinoma. <i>Eur Urol</i> 2019;75:538-540. <i>European Urology</i> , 2019, 75, e162-e163.	1.9	2
477	Nonneoplastic Disorders of the Urinary Bladder. , 2020, , 195-229.e11.		2
478	Prelimplantation Factor immunohistochemical expression correlates with prostate cancer aggressiveness. <i>International Journal of Biological Markers</i> , 2020, 35, 82-90.	1.8	2
479	Narrative review: predicting future molecular and clinical profiles of prostate cancer in the United States. <i>Translational Andrology and Urology</i> , 2021, 10, 1562-1568.	1.4	2
480	An update on immunotherapy in uro-oncology. <i>Expert Review of Precision Medicine and Drug Development</i> , 2021, 6, 229-233.	0.7	2
481	The Pathology of Prostate Cancer. , 2010, , 45-83.		2
482	Emerging molecular pathways and targets in neuroendocrine prostate cancer. <i>Translational Cancer Research</i> , 2016, 5, S282-S285.	1.0	2
483	Contemporary grading of prostate cancer: 2017 update for pathologists and clinicians. <i>Asian Journal of Andrology</i> , 2019, 21, 19.	1.6	2
484	Multilocular cystic renal cell neoplasms of low malignant potential. <i>Analytical and Quantitative Cytopathology and Histopathology</i> , 2012, 34, 235-8.	0.2	2
485	Contemporary update on pathology-related issues of adult renal neoplasms. <i>Analytical and Quantitative Cytopathology and Histopathology</i> , 2014, 36, 1-8.	0.2	2
486	Prostatic and urothelial metastasis in the same lymph node: a case report. <i>Analytical and Quantitative Cytopathology and Histopathology</i> , 2015, 37, 139-43.	0.2	2

#	ARTICLE	IF	CITATIONS
487	Re: Aurélien Descazeaud, Marc Zerbib, Thierry Flam et al. Can pT0 Stage of Prostate Cancer be Predicted before Radical Prostatectomy? <i>Eur Urol</i> 2006;50:1248-53. <i>European Urology</i> , 2007, 52, 294-295.	1.9	1
488	Editorial Comment on: Prevalence of a Tertiary Gleason Grade and Its Impact on Adverse Histopathologic Parameters in a Contemporary Radical Prostatectomy Series. <i>European Urology</i> , 2009, 55, 402.	1.9	1
489	Reply to JosÃ© I. Lopez's Letter to the Editor re: Rodolfo Montironi, Liang Cheng, Antonio Lopez-Beltran, et al. Stage pT0 in Radical Prostatectomy with No Residual Carcinoma and with a Previous Positive Biopsy Conveys a Wrong Message to Clinicians and Patients: Why Is Cancer Not Present in the Radical Prostatectomy Specimen? <i>Eur Urol</i> 2009;56:272-4. <i>European Urology</i> , 2010, 57, e22-e23.	1.9	1
490	â€œNo Pay, No Playâ€ or From â€œDefensive or Passive Pathologyâ€ to â€œActive, Clinically Oriented Pathologyâ€. <i>Archives of Pathology and Laboratory Medicine</i> , 2012, 136, 1474-1475.	2.5	1
491	Re: â€œNo Pay, No Playâ€: The End of Professional Ethics in Pathology?. <i>European Urology</i> , 2012, 61, 424-425.	1.9	1
492	Editorial Comment from Dr Montironi <i>et al.</i> to Malignant mixed epithelial and stromal tumor of the kidney: Report of the first male case. <i>International Journal of Urology</i> , 2013, 20, 451-452.	1.0	1
493	Conceptual Evolution in Cancer Biology. , 2013, , 77-109.		1
494	Morphological Analysis of Radical Prostatectomy Specimens: Recent Topics Relevant to Prognosis. <i>European Journal of Inflammation</i> , 2013, 11, 15-22.	0.5	1
495	Editorial (Mini-Thematic Issue: Morphological and Molecular Backgrounds for Personalized Therapies) <i>Tj ETQq1 1 0.784314 rgBT /Ove</i>	2.1	1
496	The Prostate and Seminal Vesicles. , 2015, , 195-310.		1
497	Cysts and Epithelial Proliferations of the Testicular Collecting System. , 2016, , 171-189.		1
498	Re: Umberto Leone Roberti Maggiore, Simone Ferrero, Massimo Candiani, et al. Bladder Endometriosis: A Systematic Review of Pathogenesis, Diagnosis, Treatment, Impact on Fertility, and Risk of Malignant Transformation. <i>Eur Urol</i> 2017;71:790-807. <i>European Urology</i> , 2017, 72, e139-e141.	1.9	1
499	Prospects for precision therapy of bladder urothelial carcinoma. <i>Expert Review of Precision Medicine and Drug Development</i> , 2017, 2, 261-274.	0.7	1
500	Re: Daniel M. Geynisman. Anti-programmed cell death protein 1 (PD-1) antibody nivolumab leads to a dramatic and rapid response in papillary renal cell carcinoma with sarcomatoid and rhabdoid features. <i>Eur Urol</i> 2015;68:912-4. <i>European Urology</i> , 2017, 71, e27-e28.	1.9	1
501	â™™,â™™ Prostate and Breast Pathology: Similarities and Differences. , 2019, , 155-170.		1
502	Renal Cell Carcinoma: genomic landscape and clinical implications. <i>Expert Review of Precision Medicine and Drug Development</i> , 2020, 5, 95-100.	0.7	1
503	Re: Alfonso GÃmez de LiaÃo Lista, Nick van Dijk, Guillermo de Velasco Oria de Rueda, et al. Clinical Outcome After Progressing to Frontline and Second-line Antiâ€PD-1/PD-L1 in Advanced Urothelial Cancer. <i>Eur Urol</i> 2020;77:269-76. <i>European Urology</i> , 2021, 79, e17-e19.	1.9	1
504	Re: Timothy D. Jones, Liang Cheng. Histologic Grading of Bladder Tumors: Using Both the 1973 and 2004/2016 World Health Organization Systems in Combination Provides Valuable Information for Establishing Prognostic Risk Groups. <i>Eur Urol</i> 2021;79:489-91. <i>European Urology</i> , 2021, 79, e172-e173.	1.9	1

#	ARTICLE	IF	CITATIONS
505	The Coronavirus Disease 2019 (COVID-19) Pandemic's Impact on Social Interaction in Pathology. Archives of Pathology and Laboratory Medicine, 2021, 145, 1049-1050.	2.5	1
506	Digital whole mount sections of the prostate: heading towards new ways of communicating with clinicians and patients without microscope. Minerva Urology and Nephrology, 2021, , .	2.5	1
507	Re: Bas W.G. van Rhijn, Anouk E. Hentschel, Johannes Brähler, et al. Prognostic Value of the WHO1973 and WHO2004/2016 Classification Systems for Grade in Primary Ta/T1 Non-muscle-invasive Bladder Cancer: A Multicenter European Association of Urology Non-muscle-invasive Bladder Cancer Guidelines Panel Study. Eur Urol Oncol 2021;4:182-91. European Urology Oncology. 2021, 4, 671-673.	5.4	1
508	Pathology of tumors of the renal pelvis and ureter and the urethra. , 2007, , 235-242.		1
509	Liquid biopsies in renal cell carcinoma with focus on epigenome analysis. Annals of Translational Medicine, 2019, 7, S194-S194.	1.7	1
510	Paratesticular well-differentiated liposarcoma initially diagnosed as fibrous pseudotumour. Indian Journal of Pathology and Microbiology, 2020, 63, 53.	0.2	1
511	Rare lesions and tumors of the urinary bladder. Selected issues. Tumori, 2012, 98, 274-7.	1.1	1
512	Artificial intelligence and prostate cancer: Advances and challenges. Urologia, 2021, , 039156032110624.	0.7	1
513	Editorial Comment on: Validation of the Contemporary Epstein Criteria for Insignificant Prostate Cancer in European Men. European Urology, 2008, 54, 1311-1312.	1.9	0
514	Editorial Comment on: Comparing the Gleason Prostate Biopsy and Gleason Prostatectomy Grading System: The Lahey Clinic Medical Center Experience and an International Meta-analysis. European Urology, 2008, 54, 380-381.	1.9	0
515	Editorial Comment on: Cytological Punctures in the Diagnosis of Renal Tumours: A Study on Accuracy and Reproducibility. European Urology, 2009, 55, 197-198.	1.9	0
516	Editorial Comment on: Platelet Microparticles: A Potential Predictive Factor of Survival in Hormone-Refractory Prostate Cancer Patients Treated with Docetaxel-Based Chemotherapy. European Urology, 2009, 56, 484-485.	1.9	0
517	Reply to Kiril Trpkov, Asli Yilmaz Letter to the Editor re: Rodolfo Montironi, Liang Cheng, Antonio Lopez-Beltran, et al. Original Gleason System Versus 2005 ISUP Modified Gleason System: The Importance of Indicating Which System Is Used in the Patient's Pathology and Clinical Reports. Eur Urol 2010;58:369-73. European Urology. 2011, 59, e7-e8.	1.9	0
518	Reply to Jérôme Verine's Letter to the Editor re: Rodolfo Montironi, Antonio Lopez-Beltran, Liang Cheng, Marina Scarpelli. Re: Multilocular Cystic Renal Cell Carcinoma with Focus on Clinical and Pathobiological Aspects. Eur Urol 2013;63:400-1. European Urology, 2013, 63, e74-e75.	1.9	0
519	Reply to Jérôme Verine's Letter to the Editor re: Rodolfo Montironi, Marina Scarpelli, Liang Cheng, et al. Immunoglobulin G4-related Disease in Genitourinary Organs: An Emerging Fibroinflammatory Entity Often Misdiagnosed Preoperatively as Cancer. Eur Urol. In press. http://dx.doi.org/10.1016/j.eururo.2012.11.056 . European Urology. 2013, 64, e53-e54.	1.9	0
520	Tumors of the Urinary Bladder. , 2013, , 85-100.		0
521	The International Society of Urological Pathology Consensus Conference regarding the classification, prognostic factors, staging, and immunohistochemical and molecular assessment of adult renal tumors. Revista Espanola De Patologia, 2015, 48, 90-96.	0.2	0
522	Prostate cancer grading in 2016. Minerva Urology and Nephrology, 2016, 69, 1-4.	2.5	0

#	ARTICLE	IF	CITATIONS
523	Re: Idir Ouzaid and Karim Bensalah. Results of the First Trial Assessing Adjuvant Tyrosine Kinase Inhibitors in Renal Cell Carcinoma Do Not reASSURE. Eur Urol 2015;68:542-3. European Urology, 2016, 70, e69-e70.	1.9	0
524	Handling of the Surgical Specimen and Pathology Reporting of Penile Neoplasms. , 2016, , 275-280.		0
525	Handling of the Surgical Specimen and Pathology Reporting of Malignant Germ Cell and Sex Cord-Stromal Tumors of the Testis. , 2016, , 165-170.		0
526	In reply to: letter to the editor entitled: primary pure lymphoepithelioma-like carcinoma of the ureter. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2017, 471, 561-562.	2.8	0
527	Re: A Novel Tool for Predicting Extracapsular Extension During Graded Partial Nerve Sparing in Radical Prostatectomy. European Urology, 2018, 73, 978-980.	1.9	0
528	Quick steps toward precision medicine in renal cell carcinoma. Expert Review of Precision Medicine and Drug Development, 2018, 3, 283-285.	0.7	0
529	â™,â™€The Prostatic Utricle and Endometrioid Prostate Cancer. , 2019, , 123-127.		0
530	â™,â™€Cystic Lesions of the Prostate and Lower Genitourinary Tract versus Female Gynecologic Tract Lesions: Similarities and Differences. , 2019, , 128-139.		0
531	â™,â™€Ectopic Prostatic Tissue. , 2019, , 145-149.		0
532	â™,â™€Clear Cell Tumors of the Kidney and the Gynecologic Tract. , 2019, , 173-188.		0
533	â™,â™€Similarities and Differences in Neuroendocrine Tumors of the Male and Female Genital Tracts and Urinary Tract. , 2019, , 233-244.		0
534	â™,â™€Transitional Cell Tumors of the Bladder. , 2019, , 254-273.		0
535	â™,â™€Micropapillary Urothelial Carcinoma of the Bladder versus Gynecologic Tract Carcinomas with Micropapillary Features: Similarities and Differences. , 2019, , 278-282.		0
536	â™,â™€Pathology of the Female and Male Urethra. , 2019, , 285-303.		0
537	â™,â™€Müllerian Lesions of the Bladder: Endometriosis, Endosalpingiosis, Endocervicosis, and Müllerianosis. , 2019, , 304-309.		0
538	â™,â™€Clear Cell Carcinoma of the Urinary Tract vs. Clear Cell Carcinoma of the Ovary: Similarities and Differences. , 2019, , 310-315.		0
539	â™,â™€Cystic and Solid Tumors of the Urachus vs. Gynecologic Tract Tumors: Similarities and Differences. , 2019, , 316-330.		0
540	â™,â™€Secondary Tumors of the Male and Female Genital Tracts and Urinary Tract: Similarities and Differences. , 2019, , 397-410.		0

#	ARTICLE	IF	CITATIONS
541	Re: Lorenzo Marconi, Thomas Stonier, Rafael Tourinho-Barbosa, et al. Robot-assisted Radical Prostatectomy After Focal Therapy: Oncological, Functional Outcomes and Predictors of Recurrence. Eur Urol 2019;76:27-30. European Urology, 2020, 77, e100-e102.	1.9	0
542	Re: Maria Chiara Sighinolfi, Bernardo Rocca's Words of Wisdom re: EAU Guidelines: Prostate Cancer 2019. Mottet N, van den Bergh RCN, Briers E, et al. https://uroweb.org/guideline/prostate-cancer/ . Eur Urol 2019;76:871. European Urology, 2020, 77, e122-e127.	1.9	0
543	Let us not forget about our past contributions to the field of prostatic neoplasms: To some extent what we value now was already there. Pathology Research and Practice, 2021, 219, 153377.	2.3	0
544	The Wide Spectrum of Oncocytic Changes and Tumors in the Kidney: Splitting and Lumping. Pathobiology, 2021, 88, 1-4.	3.8	0
545	RE: Noninvasive papillary urothelial neoplasia (NIPUN): Renaming cancer, by Jones TD and Cheng L, https://doi.org/10.1016/j.urolonc.2020.12.007 (Low grade papillary intra-urothelial neoplasia). Urologic Oncology: Seminars and Original Investigations, 2021, 39, 308-309.	1.6	0
546	Re: Scott Wilkinson, Huihui Ye, Fatima Karzai, et al. Nascent Prostate Cancer Heterogeneity Drives Evolution and Resistance to Intense Hormonal Therapy. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2021.03.009 . European Urology, 2021, 80, e81-e82.	1.9	0
547	What's the future in uropathology. Urologia, 2021, 88, 265-266.	0.7	0
548	Urinary Bladder. , 2006, , 1175-1218.		0
549	Renal Pelvis, Ureter, and Urethra. , 2011, , 1567-1579.		0
550	Urinary Bladder. , 2011, , 1515-1565.		0
551	Role of Pathology in the Multidisciplinary Management of Patients with Prostate Cancer. , 2014, , 29-41.		0
552	Lipomatous Hypertrophy of the Cardiac Interatrial Septum. American Journal of Forensic Medicine and Pathology, 1997, 18, 206-207.	0.8	0
553	Tumors and Tumor-Like Conditions of Urinary Bladder, Renal Pelvis, Ureter and Urethra. , 2015, , 63-194.		0
554	Urinary Bladder. , 2016, , 1681-1735.		0
555	Renal Pelvis, Ureter, and Urethra. , 2016, , 1737-1750.		0
556	Urinary Tract Pure Squamous Cell Carcinoma. Encyclopedia of Pathology, 2019, , 1-4.	0.0	0
557	Urothelial Carcinoma: Lipid-Rich Type. Encyclopedia of Pathology, 2019, , 1-2.	0.0	0
558	Cystitis After Chemotherapy. Encyclopedia of Pathology, 2019, , 1-3.	0.0	0

#	ARTICLE	IF	CITATIONS
559	Prostatic Acinar Adenocarcinoma, Sarcomatoid Variant. Encyclopedia of Pathology, 2019, , 1-4.	0.0	0
560	Urothelial Carcinoma, Lymphoepithelioma-Like Type. Encyclopedia of Pathology, 2019, , 1-3.	0.0	0
561	Urothelial Carcinoma in Situ. Encyclopedia of Pathology, 2019, , 1-4.	0.0	0
562	Perivascular Epithelioid Cell Tumor. Encyclopedia of Pathology, 2019, , 1-2.	0.0	0
563	Cystitis After Radiation. Encyclopedia of Pathology, 2019, , 1-3.	0.0	0
564	Urothelial Carcinoma, Sarcomatoid Type. Encyclopedia of Pathology, 2019, , 1-3.	0.0	0
565	Urothelial Carcinoma, Giant Cell Type. Encyclopedia of Pathology, 2019, , 1-2.	0.0	0
566	Urachal Carcinoma. Encyclopedia of Pathology, 2019, , 1-4.	0.0	0
567	Renal Cell Carcinoma, Unclassified. Encyclopedia of Pathology, 2019, , 1-2.	0.0	0
568	Urothelial Carcinoma, Plasmacytoid Type. Encyclopedia of Pathology, 2019, , 1-4.	0.0	0
569	Bladder Cloacal Extrophy. Encyclopedia of Pathology, 2019, , 1-3.	0.0	0
570	Papillary Urothelial Neoplasm of Low Malignant Potential. Encyclopedia of Pathology, 2019, , 1-3.	0.0	0
571	Inverted Urothelial Papilloma. Encyclopedia of Pathology, 2019, , 1-4.	0.0	0
572	Urinary Tract Adenocarcinoma. Encyclopedia of Pathology, 2020, , 1-5.	0.0	0
573	Staging and Reporting of Renal Cell Carcinomas. , 2020, , 423-436.		0
574	Specimen Handling: Radical and Partial Nephrectomy Specimens. , 2020, , 411-422.		0
575	Urothelial Carcinoma, Micropapillary Type. Encyclopedia of Pathology, 2020, , 1-3.	0.0	0
576	Urothelial Carcinoma, Nested Type. Encyclopedia of Pathology, 2020, , 1-3.	0.0	0

#	ARTICLE	IF	CITATIONS
577	Urothelial Carcinoma, Invasive. Encyclopedia of Pathology, 2020, , 1-7.	0.0	0
578	Urinary Tract Small Cell Neuroendocrine Carcinoma. Encyclopedia of Pathology, 2020, , 1-4.	0.0	0
579	Bladder Cloacal Extrophy. Encyclopedia of Pathology, 2020, , 20-22.	0.0	0
580	Papillary Urothelial Carcinoma. Encyclopedia of Pathology, 2020, , 252-255.	0.0	0
581	Urothelial Carcinoma, Plasmacytoid Type. Encyclopedia of Pathology, 2020, , 486-489.	0.0	0
582	Urinary Tract Pure Squamous Cell Carcinoma. Encyclopedia of Pathology, 2020, , 445-448.	0.0	0
583	Cystitis After Radiation. Encyclopedia of Pathology, 2020, , 49-51.	0.0	0
584	Urothelial Carcinoma, Lymphoepithelioma-Like Type. Encyclopedia of Pathology, 2020, , 477-479.	0.0	0
585	Urothelial Carcinoma, Poorly Differentiated. Encyclopedia of Pathology, 2020, , 489-491.	0.0	0
586	Urothelial Carcinoma, Clear Cell (Glycogen-Rich) Type. Encyclopedia of Pathology, 2020, , 1-3.	0.0	0
587	Urothelial Carcinoma, Micropapillary Type. Encyclopedia of Pathology, 2020, , 481-484.	0.0	0
588	Urothelial Tumors in Children and Young Adults. Encyclopedia of Pathology, 2020, , 498-501.	0.0	0
589	Inverted Urothelial Papilloma. Encyclopedia of Pathology, 2020, , 158-161.	0.0	0
590	Pathology of the Benign and Malignant Diseases of the Prostate. , 2020, , 1-12.		0
591	Urinary Tract Small Cell Neuroendocrine Carcinoma. Encyclopedia of Pathology, 2020, , 448-451.	0.0	0
592	Urothelial Carcinoma, Lipid-Rich Type. Encyclopedia of Pathology, 2020, , 475-477.	0.0	0
593	Mucinous Metaplasia. Encyclopedia of Pathology, 2020, , 1-3.	0.0	0
594	Urothelial Tumors in Children and Young Adults. Encyclopedia of Pathology, 2020, , 1-4.	0.0	0

#	ARTICLE	IF	CITATIONS
595	Urothelial Carcinoma, Nested Type. Encyclopedia of Pathology, 2020, , 484-486.	0.0	0
596	Prostatic Acinar Adenocarcinoma, Sarcomatoid Variant. Encyclopedia of Pathology, 2020, , 319-322.	0.0	0
597	Papillary Urothelial Neoplasm of Low Malignant Potential. Encyclopedia of Pathology, 2020, , 255-256.	0.0	0
598	Mucinous Metaplasia. Encyclopedia of Pathology, 2020, , 211-212.	0.0	0
599	Urachal Carcinoma. Encyclopedia of Pathology, 2020, , 430-433.	0.0	0
600	Urothelial Carcinoma, Giant Cell Type. Encyclopedia of Pathology, 2020, , 468-469.	0.0	0
601	Urinary Tract, Normal Histology. Encyclopedia of Pathology, 2020, , 456-460.	0.0	0
602	Urethral Polyp, Prostatic Type. Encyclopedia of Pathology, 2020, , 437-438.	0.0	0
603	Urothelial Carcinoma with Divergent Differentiation. Encyclopedia of Pathology, 2020, , 463-466.	0.0	0
604	Urinary Tract, Normal Histology. Encyclopedia of Pathology, 2020, , 1-5.	0.0	0
605	Papillary Urothelial Carcinoma. Encyclopedia of Pathology, 2020, , 1-3.	0.0	0
606	Perivascular Epithelioid Cell Tumor. Encyclopedia of Pathology, 2020, , 298-299.	0.0	0
607	Cystitis, Cystic, Glandularis, and Proliferative. Encyclopedia of Pathology, 2020, , 51-53.	0.0	0
608	Urothelial Carcinoma, Sarcomatoid Type. Encyclopedia of Pathology, 2020, , 491-493.	0.0	0
609	Urothelial Carcinoma In Situ. Encyclopedia of Pathology, 2020, , 460-463.	0.0	0
610	Urothelial Carcinoma with Divergent Differentiation. Encyclopedia of Pathology, 2020, , 1-3.	0.0	0
611	Urinary Tract Adenocarcinoma. Encyclopedia of Pathology, 2020, , 439-443.	0.0	0
612	Urethral Caruncle. Encyclopedia of Pathology, 2020, , 436-437.	0.0	0

#	ARTICLE	IF	CITATIONS
613	Urothelial Carcinoma, Invasive. Encyclopedia of Pathology, 2020, , 469-475.	0.0	0
614	Renal Cell Carcinoma, Unclassified. Encyclopedia of Pathology, 2020, , 342-344.	0.0	0
615	Cystitis After Chemotherapy. Encyclopedia of Pathology, 2020, , 47-49.	0.0	0
616	Urothelial Carcinoma, Clear Cell (Glycogen-Rich) Type. Encyclopedia of Pathology, 2020, , 466-467.	0.0	0
617	Spectrum of incipient (or precursor) lesions in the mucosa of the seminal vesicles. Pathology Research and Practice, 2022, 229, 153737.	2.3	0